Podcasts about Ketamine

If you're on antidepressants and your sex drive has completely disappeared, I want you to know that you're not broken, and you don't have to choose between feeling mentally well and having a fulfilling sex life. SSRIs like Lexapro, Zoloft, and Prozac are genuinely life-changing for so many people, but nobody warns you that they can tank your desire, make orgasms nearly impossible, and quietly wreck your relationship in the process. In this episode, I'm breaking down exactly why this happens, and more importantly, what you can actually do about it. From simple timing hacks to alternative treatments that are showing real promise. In this episode, you'll learn: • Why SSRIs suppress desire and arousal on a hormonal level — and the one hack that can reduce side effects as soon as tonight • How to rebuild your sex drive when both you and your partner are medicated (yes, this is more common than you think) • The alternative treatments — TMS therapy, ketamine, and psilocybin — that are helping people get off antidepressants entirely More Dr. Emily:  • Shop With Emily! Explore Emily's favorite toys, pleasure accessories, bedroom essentials, and more — designed to support your pleasure and confidence. Free shipping on orders $99+ (some exclusions apply). • Join the SmartSX Membership: Access exclusive sex coaching, live expert sessions, community building, and tools to enhance your pleasure and relationships with Dr. Emily Morse. • Interested in 1:1 Coaching with Emily? Go to sexwithemily.com/coaching to apply!  • Sex With Emily Guides: Explore pleasure, deepen connections, and enhance intimacy using these Sex With Emily downloadable guides. • The only sex book you'll ever need: Smart Sex: How to Boost Your Sex IQ and Own Your Pleasure • Want more? Visit the Sex With Emily Website • Let's get social: Instagram | X | Facebook | TikTok | Threads | YouTube • Let's text: Sign up here • Want me to slide into your email inbox? Sign Up Here for sex tips on the regular. Chapters: 0:00 - Intro 0:31 - Sarah's Story: The SSRI Sex Drive Dilemma 3:50 - Why SSRIs Kill Your Libido (The Science) 6:50 - How Common Is This? Depression & Sex Stats 14:00 - Side Effects Breakdown: Vulva vs. Penis Owners 15:50 - Practical Hacks: Timing, Alcohol & Cannabis 20:53 - Alternative Treatments: TMS, Ketamine & Psychedelics 25:31 - Both Partners on SSRIs? How to Rebuild Intimacy 31:58 - The 36 Questions Study That Reignites Closeness 33:37 - Perimenopause, Hormones & Anti-Depressants at 48 Learn more about your ad choices. Visit megaphone.fm/adchoices

Mazel morons! This week we welcome Dr. Craig Koniver (Josh's wellness wizard- not the Southern Charm star) to break down peptides, GLP-1s, methylene blue, muscle loss myths, and why half the internet is buying research-grade chemicals with “not for human use” on the label. Plus: bungalow discourse, Jewish kiddush engineering, microdosing Judaism, Botox myths, hair loss panic, and why Ben once accidentally did ketamine in a bathroom for 90 minutes. What are ya nuts?!Write in your questions to goodguyspodcast1@gmail.com!Follow us on Instagram and TikTok! Sponsors:Grab Goodwipes for free at Walmart so you can upgrade your restroom routine! Buy any one, two or three pack in Walmart or Walmart.com, text them your receipt, and get reimbursed almost immediately. For more details, head to goodwipes.com/GOODGUYS.Right now, Mizzen & Main is offering our listeners 20% off your first purchase at mizzenandmain.com, promo code goodguys20Please note that this episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct or indirect financial interest in products or services referred to in this episode.Produced by Dear Media.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Chris Sullivan with a Chokepoint: the largest transfer station in Snohomish will be closed for a month // Luke Duecy with a Tech Talk: Looking at the rise of novelty betting // Dr. Lucinda Grande on the use of ketamine as a treatment for fentanyl withdrawal // Charlie Commentary on how the new tax system is likely to drive businesses out of the state // Paul Queary with a legislative update // Gee Scott on whether the Seahawks will go to the White House

This hypnosis session was for a client suffering from extreme post-COVID fatigue, and Adam uses a fairytale with many levels of metaphor, partly linked to the Lion King universe, and a metaphor of quicksand, to help them feel empowered on their healing journey. To access a subscriber-only version with no intro, outro, explanation, or ad breaks and 24 hours earlier than everyone else, tap 'Subscribe' nearby or click the following link.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://creators.spotify.com/pod/profile/adam-cox858/subscribe⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

PsychopharmaPearls is NEI's focused podcast series highlighting the clinical insights that can sharpen your prescribing decisions. In this episode, Dr. Andy Cutler talks with Dr. Lisa Harding about how to choose between IV ketamine and intranasal esketamine for patients with difficult-to-treat depression. They unpack the differences that truly matter in practice—from patient selection and monitoring to access, cost, and common missteps. Tune in for practical pearls you can immediately apply to select the right treatment for the right patient.  Lisa Harding, MD is a board-certified psychiatrist and nationally recognized depression specialist with deep expertise in interventional psychiatry. She has performed more than 4,000 procedures, including electroconvulsive therapy (ECT), intravenous ketamine, intranasal esketamine, and transcranial magnetic stimulation (TMS). Dr. Harding is known for her thoughtful approach to complex, treatment-resistant depression, integrating advanced somatic therapies, psychopharmacology, and psychotherapy. She serves as an Assistant Clinical Professor of Psychiatry at Yale University in New Haven, Connecticut.  Andrew J. Cutler, MD is a leading psychiatrist, psychopharmacology expert, and clinical researcher with decades of experience in CNS drug development. As Chief Medical Officer of Neuroscience Education Institute and EMA Wellness, he brings frontline clinical insight together with deep knowledge of the evidence base. Dr. Cutler is widely recognized for translating research into practical guidance for everyday practice and serves as a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Resources  Sanacora G et al. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry 2017;74(4):399-405. doi:10.1001/jamapsychiatry.2017.0080  McIntyre RS et al. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. Am J Psychiatry 2021;178(5):383-399. doi:10.1176/appi.ajp.2020.20081251    Save $100 on registration for 2026 NEI Spring Congress with code NEIPOD26  Register today at nei.global/spring    Never miss an episode!

Finley joins Believe in People to share his lived experience of ketamine addiction and recovery, and how a substance that first felt functional and harmless became physically and psychologically destructive.We explore how early use of cannabis and cocaine progressed into ketamine, why it can feel controlled at first, and how denial allows harm to escalate unnoticed. Finley explains ketamine bladder in clear, practical terms, the impact on family and identity, and the turning point that forced change.This is a grounded conversation about stigma, youth culture and what real recovery requires beyond detox.#believeinpeople #believeinpeoplepodcast #believeinpeopleextra #ketamineClick here to text our host, Matt, directly!

Every ketamine clinic goes through predictable life cycle stages, just like human development. And understanding which stage you're in changes everything about how you make decisions.In this episode, we introduce a framework for understanding the four distinct phases every ketamine clinic experiences: infancy (startup survival), teenage years (identity formation), prime adult years (optimization and scaling), and midlife and beyond (legacy and transition planning).We walk you through what to expect at each stage and the questions to ask yourself to identify where your clinic is right now. This helps you make strategic decisions aligned with your values rather than reactive choices based on fear or pressure.Whether you're contemplating opening a clinic, surviving startup chaos, establishing systems, or considering your exit strategy, this framework helps you anticipate what's coming next and prepare accordingly..This isn't theoretical business advice. We've experienced several of these stages firsthand with our own clinic and have supported many providers as they navigate phases we're still approaching ourselves. What You'll Learn:

Kratom. Ketamine. They're not viewed the same way as heroin or fentanyl. They're often described as “natural.” “Therapeutic.” “Safer.” And yet — families are calling us blindsided. In this episode, we unpack the growing problem of addiction to substances that are widely used, loosely regulated, and often not treated with the same seriousness as traditional drugs of abuse. We talk about: * Why kratom and ketamine addiction catch families off guard * The dangerous illusion of “legal means safe” * What makes withdrawal from these substances uniquely difficult * The rehab dilemma when a substance isn't classified as a controlled drug * Why many treatment centers are not equipped to handle these cases properly * What families can actually do when they realize this has gone too far The truth is — addiction doesn't care whether something is scheduled, prescribed, plant-based, or trendy. And when the system doesn't clearly define the problem, families are left confused, dismissed, and struggling to find real help. If you love someone who is using kratom or ketamine and you're wondering, “Is this really that serious?” — this episode is for you. You are not crazy. And you are not overreacting.

This hypnosis session was for a client suffering from extreme post-COVID fatigue and helps them experience a virtual ketamine infusion therapy treatment that mimics their own experience of ketamine therapy to amplify the results without actually using ketamine.To access a subscriber-only version with no intro, outro, explanation, or ad breaks and 24 hours earlier than everyone else, tap 'Subscribe' nearby or click the following link.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://creators.spotify.com/pod/profile/adam-cox858/subscribe⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Rosamund Pike, the Emmy and Golden Globe winner, is known for standout roles in Saltburn, her Oscar nominated lead in Gone Girl, and Made in Dagenham. Next month she stars on the West End stage, coming back to the role of Jessica Parks, the maverick judge at the heart of the National Theatre's hit play Inter Alia, also filmed for NT Live screenings. She joined Anita Rani to discuss her role that explores motherhood, masculinity and the complexities of justice.It's more than a decade since Nadiya Hussain became a household name after winning the Great British Bake Off. Since then, she's fronted her own cookery shows, written more than a dozen cookbooks and a series of children's books. Her latest collection of recipes is called Quick Comforts, and Nadiya joined presenter Clare McDonnell to talk about finding comfort in food, her career so far and lots more.In December 2024, Dominque Pelicot and 46 other men were found guilty of the aggravated rape of his wife Gisèle. Another two were found guilty of attempted rape and a further two were found guilty of sexual assault. Dominque had drugged Gisèle with medication without her knowledge, raped her and invited other men to rape her, filming as they did so. At least another 20 men who took part in these rapes could not be identified. Waving her right to anonymity, Gisèle Pelicot declared that shame has to change sides. Despite her becoming a household name, not only in her native France but around the world, very little was known about Gisèle herself. She has written her memoir, A Hymn to Life, with writer Judith Perrignon and Judith joins Nuala McGovern to discuss.Dr Punam Krishan is a Glasgow based NHS GP and the resident doctor on the BBC's Morning Live programme. Back in 2024 she was a contestant on Strictly Come Dancing where she was the first dancer to perform a Bollywood routine. But six months ago, at the age of 42, she was diagnosed with breast cancer, and has since gone through treatment. She has recently written about how being a doctor didn't prepare her for the experience of being a patient. Dr Punam joined Anita to discuss.Ketamine has become a worryingly popular recreational drug among young people, and the consequences can be devastating. That's according to a specialist NHS clinic which reports that some teenagers suffer such severe bladder damage from taking it, that some rely on incontinence pads. To discuss the implications, Anita was joined by Dr Alison Downey, Consultant Urologist at Mid Staffs NHS Foundation Trust, who is treating young people with ketamine related bladder problems. Also joining them is Eva, who has stopped using ketamine and is receiving support from the hub.The award-winning internationally renowned Welsh harpist and composer Catrin Finch first came to prominence in her early 20s as the official Royal Harpist to King Charles, the-then Prince of Wales. She achieved chart success with her No. 1 recording of Bach's Goldberg Variations and has performed with many of the world's leading orchestras. Catrin, who began playing the harp at just six years old, has a new album, Notes to Self, a series of reflective and deeply personal new tracks she has composed for Katy, her 13-year-old-self. She joined Nuala and performed live in the studio. Presenter: Anita Rani Producer: Annette Wells

Kari reconnected with her birth mother in her 40s and finally began to understand the suffering for which she had no words. This is a story of adoption and reunification, of forgetting and remembering, of finding a truth without words in the wisdom of the body.  Kari's birth mother was able to see something deep in Kari that she had never had words for….and thus began her path toward healing.Support the show! https://www.buzzsprout.com/396871/supportBringing Therapy into Med Management-- An intensive workshop for psych NPs and PAs, June 3-6 2026 in Ft Collinshttps://www.craigheacockmd.com/bringing-therapy-into-med-management/"I Love You, I Hate You, Are You My Mom?"  An intensive experiential workshop exploring transference and countertransference with Dr. H and Dr. Hillary McBride, June 18-20 2026 in Vancouver BChttps://www.craigheacockmd.com/i-love-you-i-hate-you-are-you-my-mom/Elemental Psychedelics Ketamine-Assisted Psychotherapy Traininghttps://www.elementalpsychedelics.com/ketaminetrainingExplore the podcast through themes, domains, formats, and speakers.The BFTA CODEX is a listener-built and curated field guide to every episode.https://bfta-codex.orgBFTA episode recommendations/Podcast pagehttps://www.craigheacockmd.com/podcast-page/Support the show

Rosamund Pike, the Emmy and Golden Globe winner, is known for standout roles in Saltburn, her Oscar nominated lead in Gone Girl, and Made in Dagenham. Next month she stars on the West End stage, coming back to the role of Jessica Parks, the maverick judge at the heart of the National Theatre's hit play Inter Alia, also filmed for NT Live screenings. She joins Anita Rani to discuss her role that explores motherhood, masculinity and the complexities of justice. Ketamine has become a worryingly popular recreational drug among young people, and the consequences can be devastating. That's according to a specialist NHS clinic which reports that some teenagers suffer such severe bladder damage from taking it, that some rely on incontinence pads. To discuss the implications, Anita is joined by Dr Alison Downey, Consultant Urologist at Mid Staffs NHS Foundation Trust, who is treating young people with ketamine related bladder problems. They are also joined by Faye Maloney, Director of The Lifeboat Recovery Community Hub, along with Eva, who has stopped using ketamine and is receiving support from the hub. The American writer Madeline Cash has just published her debut novel Lost Lambs — already an instant bestseller — and she's only 29. She won high praise from Lena Dunham, who has called her ‘a voice like no other'. Lost Lambs follows the Flynn family — parents Bud and Catherine and their three teenage daughters — whose decision to open their marriage plunges the household into chaos. As the Winter Olympics comes to a close, BBC sports reporter Katie Falkingham joins Anita to discuss the standout female athletes and record breaking performances.Presenter: Anita Rani Producer: Dianne McGregor

Melissa Lavasani & Jay Kopelman join our podcast to discuss how psychedelic policy is actually moving in Washington, DC. Lavasani leads Psychedelic Medicine Coalition, a DC-based advocacy organization focused on educating federal officials and advancing legislation around psychedelic medicine. Kopelman is CEO of Mission Within Foundation, which provides scholarships for veterans and first responders seeking psychedelic-assisted therapy retreats, often outside the United States. The conversation centers on veterans, the VA, and why that system may be the first realistic federal pathway for psychedelic care. Early Themes Lavasani describes PMC's work on Capitol Hill, including hosting events that bring lawmakers, staffers, and advocates into the same room. Her focus is steady engagement. In DC, progress often happens through repeated conversations, not headlines. Kopelman shares his background as a Marine and how his own psychedelic-assisted therapy experience led him to Mission Within. The foundation has funded more than 250 scholarships for veterans and first responders seeking treatment for PTSD, mild traumatic brain injury, depression, and addiction. They connect this work to pending veteran-focused legislation and explain why the VA matters. As a closed health system, the VA can pilot programs, gather data, and refine protocols without the pressures of private healthcare markets. Core Insights A recent Capitol Hill gathering, For Veteran Society, brought together members of Congress and leaders from the psychedelic caucus. Lavasani describes candid feedback from lawmakers. The message was clear: coordinate messaging, avoid fragmentation, and move while bipartisan interest remains. Veteran healthcare is not framed as the final goal. It is a starting point. If psychedelic therapies can demonstrate safety and effectiveness within the VA, broader adoption becomes more plausible. Kopelman raises operational realities that must be addressed: Standardized safety protocols across providers Integration support, not medication alone Clear training pathways for clinicians Real-world data beyond tightly screened clinical trials They also address recent negative headlines involving ibogaine treatment abroad. Kopelman emphasizes the need for shared learning across providers, especially when adverse events occur. Lavasani argues that inconsistency within the ecosystem can slow federal confidence. Later Discussion and Takeaways The discussion widens to federal momentum around addiction and mental health. Lavasani notes that new funding initiatives signal growing openness to innovative treatment models, even if psychedelics are not named explicitly in every announcement. Both guests stress that policy moves slowly by design. Meetings, follow-ups, and relationship building often matter more than public statements. For clinicians, researchers, operators, and advocates, the takeaways are direct: Veterans are likely the first federal pathway Public education remains essential Safety standards must be shared and transparent Integration and workforce development need attention now If psychedelic medicine enters federal systems, infrastructure will determine success. Frequently Asked Questions What do Melissa Lavasani & Jay Kopelman say about VA psychedelic policy? They argue that veteran-focused legislation offers a realistic first federal pathway for psychedelic-assisted care. Is ibogaine currently available through the VA? No. They discuss ibogaine in the context of private retreats and future possibilities, not an existing VA program. Why do Melissa Lavasani & Jay Kopelman emphasize coordination? Lawmakers respond more positively when advocates present aligned messaging and clear priorities. What safety issues are discussed by Melissa Lavasani & Jay Kopelman? They highlight the need for standardized screening, monitoring, integration support, and transparent review of adverse events. Closing Melissa Lavasani & Jay Kopelman provide a grounded look at how psychedelic policy develops inside federal systems. Their message is practical: veterans may be the first lane, but long-term success depends on coordination, safety standards, and sustained engagement. Closing This episode captures a real-time view of how federal policy could shape the next phase of the psychedelic resurgence, especially through veteran-facing legislation and VA infrastructure. Melissa Lavasani & Jay Kopelman argue that coordination, public education, and shared safety standards will shape whether access expands with credibility and care. Transcript Joe Moore: [00:00:00] Hello everybody. Welcome back to Psychedelics Today. Today we have two guests, um, got Melissa Sani from Psychedelic Medicine Coalition. We got Jake Pelman from Mission Within Foundation. We're gonna talk about I bga I became policy on a recent, uh, set of meetings in Washington, DC and, uh, all sorts of other things I'm sure. Joe Moore: But thank you both for joining me. Melissa Lavasani: Thanks for having us. Jay Kopelman: Yeah, it's a pleasure. Thanks. Joe Moore: Yeah. Um, Melissa, I wanna have you, uh, jump in. First. Can you tell us a little bit about, uh, your work and what you do at PMC? Melissa Lavasani: Yeah, so Psychedelic Medicine Coalition is, um, the only DC based Washington DC based advocacy organization dedicated to the advancing the issue of psychedelics, um, and making sure the federal government has the education they need, um, and understands the issue inside out so that they can generate good policy around, around psychedelic medicines. Melissa Lavasani: [00:01:00] Uh, we. Host Hill events. We host other convenings. Our big event every year is the Federal Summit on psychedelic medicine. Um, that's going to be May 14th this year. Um, where we talk about kinda the pressing issues that need to be talked about, uh, with government officials in the room, um, so that we can incrementally move this forward. Melissa Lavasani: Um, our presence here in Washington DC is, is really critical for this issue's success because, um, when we're talking about psychedelic medicines, um, from the federal government pers perspective, you know, they are, they are the ones that are going to initiate the policies that create a healthcare system that can properly facilitate these medicines and make sure, um, patient safety is a priority. Melissa Lavasani: And there's guardrails on this. And, um, you know, there, it's, it's really important that we have. A home base for this issue in Washington DC just [00:02:00] because, uh, this is very complicated as a lot of your viewers probably understand, and, you know, this can get lost in the mix of all the other issues that, um, lawmakers in DC are focused on right now. Melissa Lavasani: And we need to keep that consistent presence here so that this continues to be a priority for members of Congress. Joe Moore: Mm. I love this. And Jay, can you tell us a bit about yourself and mission within Foundation? Jay Kopelman: Yeah, sure. Joe, thanks. Uh, I, I am the CEO of Mission within Foundation. Prior to this, most of my adult life was spent in the military as a Marine. Jay Kopelman: And I came to this. Role after having, uh, a psychedelic assisted therapy experience myself at the mission within down in Mexico, which is where pretty much we all go. Um, we are here to help [00:03:00] provide, uh, access for veterans and first responders to be able to attend psychedelic assisted therapy retreats to treat issues like mild TBI, post-traumatic stress disorder, uh, depression, sometimes addiction at, at a very low level. Jay Kopelman: Um, and, and so we've, we've been doing this for a little more than a year now and have provided 250 plus scholarships to veterans and first responders to be able to access. These retreats and these, these lifesaving medicines. Um, we're also partnered, uh, you may or may not know with Melissa at Psychedelic Medicine Coalition to help advance education and policy, specifically the innovative, uh, therapy Centers of Excellence Act [00:04:00] that Melissa has worked for a number of years on now to bring to both Houses of Congress. Joe Moore: Thank you for that. Um, so let's chat a little bit about what this event was that just, uh, went down, uh, what, what was it two weeks ago at this point? Melissa Lavasani: Yeah. Yeah. It's called For Veteran Society and it's all, um, there's a lot of dialogue on Capitol Hill about veterans healthcare and psychedelics, but where I've been frustrated is that, you know, it was just a lot of. Melissa Lavasani: Talk about what the problems are and not a lot of talk about like how we actually propel things forward. Um, so it, at that event, I thought it was really important and we had three members of Congress there, um, Morgan Latrell, who has been a champion from day one and his time in Congress, um, having gone through the experience himself, um, [00:05:00] at Mission within, um, and then the two chairs of the psychedelic caucus, uh, Lou Correa and Jack Bergman. Melissa Lavasani: And we really got down to the nitty gritty of like w like why this has taken so long and you know, what is actually happening right now? What are the possibilities and what the roadblocks are. And it was, I thought it was a great conversation. Um, we had an interesting kind of dynamic with Latres is like a very passionate about this issue in particular. Melissa Lavasani: Um, I think it was, I think it was really. A great event. And, you know, two days later, Jack Bergman introduced his new bill for the va. Um, so it was kind of like the precursor to that bill getting introduced. And we're just excited for more and more conversations about how the government can gently guide this issue to success. Joe Moore: Hmm. Yeah. [00:06:00] That's fantastic. Um, yeah, I was a little bummed I couldn't make it, but next time, I hope. But I've heard a lot of good things and, um, it's, it sounded like there was some really important messages in, in terms of like feedback from legislators. Yeah. Yeah. Could you speak to that? Melissa Lavasani: Yeah, I mean, I think when, uh, representative Latrell was speaking, he really impressed on us a couple things. Melissa Lavasani: Um, first is that, you know, they really kind of need the advocates to. Coordinate, collaborate and come up with like a, a strategic plan, you know, without public education. Um, talking to members of Congress about this issue is, is really difficult. You know, like PMC is just one organization. We're very little mission within, very little, um, you know, we're all like, kind of new in navigating, um, this not so new issue, but new to Washington DC [00:07:00] issue. Melissa Lavasani: Um, without that public education as a baseline, uh, it's, it's, you have to spend a lot of time educating members of Congress. You know, that's like one of our things is, you know, we have to, we don't wanna tell Congress what direction to go to. We wanna provide them the information so they understand it very intimately and know how to navigate through things. Melissa Lavasani: Um, and secondly. Um, he got pretty frank with us and said, you know, we've got one cha one chance at this issue. And it's like, that's, that's kind of been like my talking point since I started. PMC is like, you have a very limited window, um, when these kind of issues pop up and they're new and they're fresh and you have a lot of the veteran community coming out and talking about it. Melissa Lavasani: And there's a lot of energy there. But now is the time to really move forward, um, with some real legislation that can be impactful. Um, but, you know, we've gotta [00:08:00] be careful. We, we forget, I think sometimes those of us who are in the ecosystem forget that our level of knowledge about these medicines and a lot of us have firsthand experience, um, with these drugs and, and our own healing journeys is, um, we forget that there is a public out there that doesn't have the level of knowledge that we all have. Melissa Lavasani: And, um. We gotta make sure that we're sticking to the right elements of, of, of what needs to happen. We need to be sure that our talking points are on track and we're not getting sideways about anything and going down roads that we don't need to talk about. It's why, um, you know, PMC is very focused on, um, moving forward veteran legislation right now. Melissa Lavasani: Not because we're a veteran organization, but because we're, we see this long-term policy track here. Um, we know where we want to get [00:09:00] to, um. Um, and watching other healthcare issues kind of come up and then go through the VA healthcare system, I think it's a really unique opportunity, um, to utilize the VA as this closed system, the biggest healthcare system in the country to evaluate, uh, how psychedelics operate within systems like that. Melissa Lavasani: And, you know, before they get into, um, other healthcare systems. What do we need to fix? What do we need to pay attention to? What's something that we're paying too much attention to that doesn't necessarily need that much attention? So it's, um, it's a real opportunity to look at psychedelic medicines within a healthcare system and obviously continue to gather the data. Melissa Lavasani: Um, Bergman's Bill emerging, uh, expanding veteran access to emerging treatments. Um, not only mandates the research, it gives the VA authority for this, uh, for running trials and, and creating programs around psychedelic medicines. But also, [00:10:00] one of the great things about it, I think, is it provides an on-ramp for veterans that don't necessarily qualify for clinical trials. Melissa Lavasani: You know, I think that's one of the biggest criticisms of clinical trials is like you're cre you're creating a vacuum for people and people don't live in a vacuum. So we don't necessarily know what psychedelics are gonna look like in real life. Um, but with this expanding veteran access bill that Bergman introduced, it provides the VA an opportunity to provide this access under. Melissa Lavasani: Um, in a, in a safe container with medical supervision while collecting data, um, while ensuring that the veteran that is going through this process has the support systems that it needs. So, um, you know, I think that there's a really unique opportunity here, and like Latrell said, like, we've got one shot at this. Melissa Lavasani: We have people's attention in Congress. Um, now's the time to start acting, and let's be really considerate and thoughtful about what we're doing with it. Joe Moore: Thanks for that, Melissa and Jay, how, [00:11:00] anything to add there on kind of your takeaways from the this, uh, last visit in dc? Jay Kopelman: Yeah, I, I think that Melissa highlighted it really well and there, there were a couple other things that I, I think, you know, you could kind of tie it all together with some other issues that we face in this country, uh, and that. Jay Kopelman: Uh, representative Correa brought up as well, but one of the things I wanted to go back and say is that veterans have kind of led this movement already, right? So, so it's a, it's a good jumping off point, right? That it's something people from both sides of the aisle, from any community in America can get behind. Jay Kopelman: You know, if you think about it, uh, in World War ii, you know, we had a million people serving our population was like, not even 200 million, but now [00:12:00] we have a population of 330 million, and at any given time there might be a million people in uniform, including the Reserve and the National Guard. So it's, it, it's an easy thing to get behind this small part of the population that is willing to sign that contract. Jay Kopelman: Where you are saying, yeah, I'm going to defend my country, possibly at the risk of my l my own life. So that's the first thing. The other thing is that the VA being a closed health system, and they don't have shareholders to answer to, they can take some risks, they can be innovative and be forward thinking in the ways that some other healthcare systems can't. Jay Kopelman: And so they have a perfect opportunity to show that they truly care for their veterans, which don't, I'm not saying they don't, but this would be an [00:13:00] opportunity to show that carrot at a whole different level. Uh, it would allow them to innovate and be a leader in something as, uh, as our friend Jim Hancock will say, you know. Jay Kopelman: When he went to the Naval Academy, they had the world's best shipbuilding program. Why doesn't the VA have the world's best care program for things like TBI and PTSD, which affects, you know, 40 something percent of all veterans, right? So, so there's, there's an opportunity here for the VA to lead from the front. Jay Kopelman: Um, the, these medicines provide, you know, reasonably lasting care where it's kind of a one and done. Whereas with the current systems, the, you know, and, and [00:14:00] again, not to denigrate the VA in any way, they're doing the best job they can with the tools in their toolbox, right? But maybe it's time for a trip to Home Depot. Jay Kopelman: Let's get some new tools. And have some new ways of fixing what's broken, which is really the way of doing things. It's not, veterans aren't broken, we are who we are. Um, but it's a, it's a way to fix what isn't working. So I, I think that, you know, given there's tremendous veteran homelessness still, you know, addiction issues, all these things that do translate to the population at large are things that can be worked on in this one system, the va that can then be shown to have efficacy, have good data, have [00:15:00] good outcomes, and, and take it to the population at large. Joe Moore: Mm-hmm. Brilliant. Thanks for that. And so there was another thing I wanted to pivot to, which is some of the recent press. So we've, um, seen a little bit of press around some, um, in one instance, some bad behavior in Mexico that a FI put out Americans thrive again, put out. And then another case there was a, a recent fatality. Joe Moore: And I think, um, both are tragic. Like we shouldn't be having to deal with this at this point. Um, but there's a lot of things that got us here. Um, it's not necessarily the operator's fault entirely, um, or even at all, honestly, like some medical interventions just carry a lot of risk. Like think, think about like, uh, how risky bypass surgery was in the nineties, right? Joe Moore: Like people were dying a lot from medical interventions and um, you know, this is a major intervention, uh, ibogaine [00:16:00] and also a lot of promise. To help people quite a bit. Um, but as of right now, there's, there's risk. And part of that risk, in my opinion, comes from the inability of organizations to necessarily collaborate. Joe Moore: Like there's no kind of convening body, sitting in the middle, allowing, um, for, and facilitating really good data sharing and learnings. Um, and I don't, I don't necessarily see an organization stepping up and being the, um, the convener for that kind of work. I've heard rumors that something's gonna happen there, and I'm, I'm hopeful I'll always wanna share my opinion on that. Joe Moore: But yeah. I don't know. Jay, from your perspective, is there anything you want to kind of speak to about, uh, these two recent incidents that Americans for Iboga kind of publicized recently? Jay Kopelman: Yeah, so I, I'll echo your sentiment, of course, that these are tragic incidents. Um, and I, [00:17:00] I think that at least in the case of the death at Ambio, AMBIO has done a very good job of talking about it, right? Jay Kopelman: They've been very honest with the information that they have. And like you said, there are risks inherent to these medicines, and it's like anything else in medicine, there are going to be risks. You know, when I went through, uh, when I, when I went through chemo, you know, there were, there are risks. You know, you don't feel well, you get sick. Jay Kopelman: Um, and, and it. There are processes in place to counter that when it happens. And there are processes and, and procedures and safety protocols in place when caring for somebody going through an ibogaine [00:18:00] journey. Uh, when I did it, we had EKG echocardiogram. You're on a heart monitor the entire time they push magnesium via iv. Jay Kopelman: You have to provide a urinalysis sample to make sure that there is nothing in your system that is going to potentially harm you. During the ibogaine, they have, uh, a cardiologist who is monitoring the heart monitors throughout the ibogaine experience. So the, the safety protocols are there. I think it's, I think it's just a matter of. Jay Kopelman: Standardizing them across all, all providers, right? Like, that would be a good thing if people would talk to one another. Um, as, as in any system, right? You've gotta have [00:19:00] some collaboration. You've gotta have standardization, you know, so, you know, they're not called standard operating procedures for nothing. Jay Kopelman: That means that in a, you know, in a given environment, everybody does things the same way. It's true in Navy and Marine Corps, air Force, army Aviation, they have standard operating procedures for every single aircraft. So if you fly, let's say the F 35 now, right? Because it's flown by the Navy, the Marine Corps, and the Air Force. Jay Kopelman: The, the emergency procedures in that airplane are standardized across all three services, so you should have the same, or, you know, with within a couple of different words, the same procedures and processes [00:20:00] across all the providers, right? Like maybe in one document you're gonna change, happy to glad and small dog to puppy, but it's still pretty much the, the same thing. Jay Kopelman: And as a service that provides scholarships to people to go access these medicines and go to these retreats, you know, my criteria is that the, this provider has to be safe. Number one, safety's paramount. It's always gotta be very safe. It should, it has to be effective. And you know, once you have those two things in place, then I have a comfort level saying, okay, yeah, we'll work with this provider. Jay Kopelman: But until those standardized processes are in place, you'll probably see these one-off things. I mean, some providers have been doing this longer than others and have [00:21:00] really figured out, you know, they've, they've cracked the code and, you know, sharing that across the spectrum would be good. Um, but just when these things happen, having a clearing house, right, where everybody can come together and talk about it, you know, like once the facts are known because. Jay Kopelman: To my knowledge, we still don't know all the facts. Like as, you know, as horrible as this is, you still have to talk about like an, has an autopsy been performed? What was found in the patient's system? You know, there, there are things there that we don't know. So we need to, we need to know that before we can start saying, okay, well this is how we can fix that, because we just don't know. Jay Kopelman: And, you know, to their credit, you know, Amio has always been safe to, to the, to the best of my knowledge. You know, I, [00:22:00] I haven't been to Ambio myself, but people that I have worked with have been there. They have observed, they have seen the process. They believe it's safe, and I trust their opinion because they've seen it elsewhere as well. Jay Kopelman: So yeah, having, having that one place where we can all come together when this happens, it, it's almost like it should be mandatory. In the military when there's a training accident, we, you know, we would have to have what's called a safety standout. And you don't do that again for a little while until you figure out, okay, how are we going to mitigate that happening again? Jay Kopelman: Believe me, you can go overboard and we don't want to do that. Like, we don't wanna just stop all care, but maybe stop detox for a week and then come back to it. [00:23:00] Joe Moore: Yeah. A dream would be, let's get like the, I don't know, 10, 20 most popular, uh, or well-known operators together somewhere and just do like a three day debrief. Joe Moore: Hey, everybody, like, here's what we see. Let's work on this together. You know how normal medicine works. And this is, it's hard because this is not necessarily, um, something people feel safe about in America talking about 'cause it's illicit here. Um, I don't understand necessarily how the operations, uh, relate to each other in Mexico, but I think that's something to like the public should dig into. Joe Moore: Like, what, what is this? And I, I'll start digging into that. Um, I, I asked a question recently of somebody like, is there some sort of like back channel signal everybody's using and there's no clear Yes. You know? Um, I think it would be good. That's just a [00:24:00] start, you know, that's like, okay, we can actually kind of say hi and watch out for this to each other. Jay Kopelman: It's not like we don't all know one another, right? Joe Moore: Yes. Jay Kopelman: Like at least three operators we're represented. At the Aspen Ibogaine meeting. So like that could be, and I think there was a panel kind of loosely related to this during Aspen Ibogaine meeting, but Joe Moore: mm-hmm. Jay Kopelman: It, you know, have a breakout where the operators can go sit down and kind of compare notes. Joe Moore: Right. Yeah. Melissa, do you have any, uh, comments on this thread here? And I, I put you on mute if you didn't see that. Um, Melissa Lavasani: all right, I'm off mute. Um, yeah, I think that Jay's hits the nail on the head with the collaboration thing. Um, I think that it's just a [00:25:00] problem across the entire ecosystem, and I think that's just a product of us being relatively new and upcoming field. Melissa Lavasani: Um, uh, it's a product of, you know. Our fundraising community is really small, so organizations feel like they are competing for the same dollars, even though their, their goals are all the same, they have different functions. Um, I think with time, I mean, let's be honest, like if we don't start collaborating and, and the federal government's moving forward, the federal government's gonna coordinate for us. Melissa Lavasani: And not, that might not necessarily be a bad thing, but, you know, we understand this issue to a whole other level that the federal government doesn't, and they're not required to understand it deeply. They just need to know how to really move forward with it the proper way. Um, but I think that it. It's really essential [00:26:00] that we all have this come together moment here so we can avoid things. Melissa Lavasani: Uh, I mean, no one's gonna die from bad advocacy. So like I've, I have a bit of an easier job. Um, but it can a, a absolutely stall efforts, um, to move things forward in Washington DC when, um, one group is saying one thing, another group is saying another thing, like, we're not quite at a point yet where we can have multiple lines of conversation and multiple things moving forward. Melissa Lavasani: Um, you know, for PMC, it's like, just let's get the first thing across the finish line. And we think that is, um, veteran healthcare. And, um, I know there's plenty of other groups out there that, that want the same thing. So, you know, I always, the reason why I put on the Federal Summit last year was I kind of hit my breaking point with a lack of collaboration and I wanted to just bring everyone in the same room and say like, all right, here are the things that we need to talk about. Melissa Lavasani: And I think the goal for this year is, um. To bring people in the same room and say, we talked about [00:27:00] we scratched the surface last year and this is where we need to really put our efforts into. And this is where the opportunities are. Um, I think that is going to, that's going to show the federal government if we can organize ourselves, that they need to take this issue really seriously. Melissa Lavasani: Um, I don't think we've done a great job at that thus far, but I think there's still plenty of time for us to get it together. Um, and I'm hoping with these two, uh, VA bills that are in the house right now and Senate is, is putting together their version of these two bills, um, so that they can move in tandem with each other. Melissa Lavasani: I think that, you know, there's an opportunity here for. Us to show the federal government as an ecosystem, Hey, we, we are so much further ahead and you know, this is what we've organized and here's how we can help you, um, that would make them buy into this issue a bit more and potentially move things forward faster. Melissa Lavasani: Uh, at this point in time, it's, I think that, [00:28:00] you know, psychedelics aren't necessarily the taboo thing that they, they used to be, but there's certainly places that need attention. Um, there's certainly conversations that need to be had, and like I said, like PMC is just one organization that can do this. Um, we can certainly organize and drive forward collaboration, but I, like we alone, cannot cover all this ground and we need the subject matter experts to collaborate with us so we can, you know, once we get in the door, we wanna bring the experts in to talk to these officials about it. Melissa Lavasani: So I. I, I really want listeners to really think about us as a convener of sorts when it comes to federal policy. Um, and you know, I think when, like for example, in the early eighties, a lot of people have made comparisons to the issue of psychedelics to the issue of AIDS research and how you have in a subject matter that's like extremely taboo and a patient population that the government [00:29:00] quite honestly didn't really care about in the early eighties. Melissa Lavasani: But what they did as an ecosystem is really organized themselves, get very clear on what they wanted the federal government to do. And within a matter of a couple years, uh, AIDS research funding was a thing that was happening. And what that, what that did was that ripple effect turned that into basically finding new therapies for something that we thought was a death, death sentence before. Melissa Lavasani: So I think. We just need to look at things in the past that have been really successful, um, and, and try to take the lessons from all of these issues and, and move forward with psychedelics. Joe Moore: Love that. And yes, we always need to be figuring out efficient approaches and where it has been successful in the past is often, um, an opportunity to mimic and, and potentially improve on that. Melissa Lavasani: Yeah. Jay Kopelman: One, one thing I think it's important to add to this part of the conversation is that, [00:30:00] you know, Melissa pointed out there are a number of organizations that are essentially doing the same thing. Jay Kopelman: Um, you know, I like to think we do things a little bit differently at Mission within Foundation in that we don't target any one specific type of service member. We, we work with all veterans. We work with first responders, but. What that leads to is that there are, as far as I've seen, nothing but good intentioned people in this space. Jay Kopelman: You know, people who really care about their patient population, they care about healing, they are trying to do a good job, and more importantly, they're trying to do good. Right? It, it, I think they all see the benefit down the road that this has, [00:31:00] pardon me, not just for veterans, but for society as a whole. Jay Kopelman: And, and ultimately that's where I would like to see this go. You know, I, I would love to see the VA take this. Take up this mantle and, and run with it and provide great data, great outcomes. You know, we are doing some data collection ourselves at Mission within foundation, albeit anecdotal based on surveys given before and after retreats. Jay Kopelman: But we're also working with, uh, Greg Fonzo down at UT Austin on a brain study he's doing that will have 40 patients in it when it's all said and done. And I think we have two more guys to put through that. Uh, and then we'll hit the 40. So there, there's a lot of good here that's being done by some really, really good people who've been doing this for a long time [00:32:00] and want to want nothing more than to, to see this. Jay Kopelman: Come to, come full circle so that we can take care of many, many, many people. Um, you know, like I say, I, I wanna work myself out of a job here. I, I just, I would love to see this happen and then I, you know, I don't have to send guys to Mexico to do this. They can go to their local VA and get the care that they need. Jay Kopelman: Um, but one thing that I don't think we've touched on yet, or regarding that is that the VA isn't designed for that. So it's gonna be a pretty big lift to get the right types of providers into the va with the knowledge, right, with the institutional knowledge of how this should be done, what is safe, what is effective, um, and then it, it's not just providing these medicines to [00:33:00] people and sending them home. Jay Kopelman: You don't just do that, you've gotta have the right therapists on the backend who can provide the integration coaching to the folks who are receiving these medicines. And I'm not just talking, I bga, even with MDMA and psilocybin, you should have a proper period of integration. It helps you to understand how this is going to affect you, what it, what the experience really meant, you know, because it's very difficult sometimes to just interpret it on your own. Jay Kopelman: And so what the experience was and what it meant to you. And, and so it will take some time to spin all that up. But once it's, once it's in place, you know, the sky's the limit. I think. Joe Moore: Kinda curious Jay, about what's, what's going on with Ibogaine at the federal level. Is there anything at VA right now? [00:34:00] Jay Kopelman: At the va? No, not with ibogaine. And, you know, uh, we, we send people specifically for IBOGAINE and five MEO, right? And, and so that, that doesn't preclude my interest in seeing this legislation passed, right? Jay Kopelman: Because it, it will start with something like MDMA or psilocybin, but ultimately it could grow to iboga, right? It the think about the cost savings at, at the va, even with psilocybin, right? Where you could potentially treat somebody with a very inexpensive dose of psilocybin or, or iboga one time, and then you, you don't have to treat them again. Jay Kopelman: Now, if I were, uh, you know, a VA therapist who's not trained in psychedelic trauma therapy. I might be worried [00:35:00] about job security, but it's like with anything, right? Like ultimately it will open pathways for new people to get that training or the existing people to get that training and, and stay on and do that work. Jay Kopelman: Um, which only adds another arrow to their quiver as far as I'm concerned, because this is coming and we're gonna need the people. It's just like ai, right? Like ai, yeah. Some people are gonna lose some jobs initially, and that's unfortunate. But productivity ultimately across all industries will increase and new jobs will be created as a result of that. Jay Kopelman: I mean, I was watching Squawk Box one morning. They were talking about the AI revolution and how there's gonna be a need for 500,000 electricians to. Build these systems that are going to work with the AI [00:36:00] supercomputers and, and so, Joe Moore: mm-hmm. Jay Kopelman: Where, where an opportunity may be lost. I think several more can be gained going forward. Melissa Lavasani: And just to add on what Jay just said there, there's nothing specific going on with Ibogaine at, at the va, but I think this administration is, is taking a real look at addiction in particular. Uh, they just launched, uh, a new initiative, uh, that's really centered on addiction treatments called the Great American Recovery. Melissa Lavasani: And, um, they're dedicating a hundred million dollars towards treating addiction as like a chronic treatable disease and not necessarily a law enforcement issue. So, um, in that initiative there will be federal grant programs for prevention and treatment and recovery. And, um, while this isn't just for psychedelic medicines, uh, I think it's a really great opportunity for the discussion of psychedelics to get elevated to the White House. Melissa Lavasani: Um, [00:37:00] there's also, previous to this announcement last week from the White House, there's been a hundred million dollars that was dedicated at, um, at ARPA h, which is. The advanced research projects, uh, agency for healthcare, um, and that is kind of an agency that's really focused on forward looking, um, treatments and technologies, uh, for, um, a, a whole slew of. Melissa Lavasani: Of issues, but this a hundred million dollars is dedicated to mental health and addiction. So there's a lot of opportunity there as well. So we, while I think, you know, some people are talking about, oh, we need a executive order on Iboga, it's like, well, you know, the, the president is thinking, um, about, you know, what issues can land with his, uh, voting block. Melissa Lavasani: And I think it's, I don't think we necessarily need a specific executive order on Iboga to call this a success. It's like, let's look at what, [00:38:00] um, what's just been announced from the White House. They're, they're all in on. Thinking creatively and finding, uh, new solutions for this. And this is kind of, this aligns with, um, HHS secretaries, uh, Robert F. Melissa Lavasani: Kennedy Junior's goals when he took on this, this role of Health Secretary. Um, addiction has been a discussion that, you know, he has personal, um, a personal tie to from his own experience. And, um, I think when this administration started, there was so much like fervor around the, the dialogue of like, everyone's talking about psychedelics. Melissa Lavasani: It was Secretary Kennedy, it was, uh, secretary Collins at the va. It was FDA Commissioner Marty Macari. And I think that there's like a lot of undue frustration within folks 'cause um, you don't necessarily snap your fingers and change happens in Washington dc This is not the city for that. And it's intentionally designed to move slow so that we can avoid really big mistakes. Melissa Lavasani: Um. [00:39:00] I think we're a year into this administration and these two announcements are, are pretty huge considering, um, you know, the, we, there are known people within domestic policy council that don't, aren't necessarily supportive of psychedelic medicine. So there's a really amazing progress here, and frustrating as it might be to, um, just be waiting for this administration to make some major move. Melissa Lavasani: I think they are making major moves like for Washington, DC These, these are major moves and we just gotta figure out how we can, um, take these initiatives and apply them to the issue of psychedelic medicines. Joe Moore: Thanks, Melissa. Um, yeah, it is, it is interesting like the amount of fervor there was at the beginning. You know, we had, uh. Kind of one of my old lawyers, Matt Zorn, jumped in with the administration. Right. And, um, you know, it was, uh, really cool to [00:40:00] see and hopeful how much energy was going on. It's been a little quiet, kind of feels like a black box a little bit, but I, you know, there was, Melissa Lavasani: that's on me. Melissa Lavasani: Maybe I, we need to be more out in public about like, what's actually happening, because I feel like, like day in and day out, it's just been, you gotta just mm-hmm. Like have that constant beat with the government. Mm-hmm. And, um, it's, it's, it's not the photo ops on the hill, it's the conversations that you have. Melissa Lavasani: It's the dinner parties you go to, it's the fundraisers you attend, you know? Mm-hmm. That's why I, I kind of have to like toot my own horn with PCs. Like, we need to be present here at, at not only on the Hill, not only at the White House, but kind of in the ecosystem of Washington DC itself. There's, it's, there are like power players here. Melissa Lavasani: There are people that are connected that can get things done, like. I mean, the other last week we had a big snow storm. I walked over to my friend's house, um, to have like a little fire sesh with them and our kids, and his next door neighbor came over. He was a member of Congress. I talked about the VA bills, like [00:41:00] we're reaching out to his office now, um, to get them, um, up to speed and hopefully get their co-sponsorship for, uh, the two VA bills. Melissa Lavasani: So, I mean, it, the little conversations you have here are just as important as the big ones with the photo ops. So, um, it, it's, it's really like, you know, building up that momentum and, and finding that time where you can really strike and make something happen. Joe Moore: Mm-hmm. Yeah. Jay, anything to add there? Jay Kopelman: Yeah, I was just gonna say that, you know, I, I, I think the fervor is still there, right? Jay Kopelman: But real life happens. Melissa Lavasani: Yes, Jay Kopelman: yes. And gets in the way, right? So, Melissa Lavasani: yeah, Jay Kopelman: I, I can't imagine how many issues. Secretary Kennedy has every day much less the president. Like there's so many things that they are dealing with on a daily basis, right? It, we, we just have to work to be the squeaky wheel in, in the right way, right. Jay Kopelman: [00:42:00] With the, with the right information at the right time. Like just inundating one of these organizations with noise, it's then it be with Informa, it just becomes noise, right? It it, it doesn't help. So when we have things to say that are meaningful and impactful, we do, and Melissa does an amazing job of that. Jay Kopelman: But, you know, it, it takes time. You know, it's, you know, we're not, this is, this is like turning an aircraft carrier, not a ski boat. Melissa Lavasani: Yeah, Joe Moore: yeah, absolutely. Um, and. It's, it's understandably frustrating, I think for the public and the psychedelic public in particular because we see all this hope, you know, we continue to get frustrated at politics. It's nothing new, right? Um, and we, we wanna see more people get well immediately. [00:43:00] And I, I kind of, Jay from the veteran perspective, I do love the kind of loud voices like, you're making me go to Mexico for this. Joe Moore: I did that and you're making me leave the country for the thing that's gonna fix me. Like, no way. And barely a recognition that this is a valid treatment. You know, like, you know, that is complicated given how medicine is structured here domestically. But it's also, let's face the facts, like the drug war kind of prevented us from being able to do this research in the first place. Joe Moore: You know? Thanks Nixon. And like, how do we actually kind of correct course and say like, we need to spend appropriately on science here so we can heal our own people, including veterans and everybody really. It's a, it's a dire situation out there. Jay Kopelman: Yeah. It, it really is. Um, you know, we were talking briefly about addicts, right? Jay Kopelman: And you know, it's not sexy. People think of addicts as people who are weak-minded, [00:44:00] right? They don't have any self-control. Um, but, but look at, look at the opioid crisis, right? That Brian Hubbard was fighting against in Kentucky for all those years. That that was something that was given to the patient by a doctor that they then became dependent on, and a lot of people died from that. Jay Kopelman: And, and so you, you know, it's, I I don't think it's fair to just put all addicts in a box. Just like it's not fair to put all veterans in a box. Just like it's not fair for doctors, put all their patients in a box. We're individuals. We, we have individual needs. Our, our health is very individual. Like, I, I don't think I should be put in the same box as every other 66-year-old that my doctor sees. Jay Kopelman: It's not fair. [00:45:00] You know, if you, if you took my high school classmates and put us all in a photo, we're all gonna have different needs, right? Like, some look like they're 76, not 66. Some look like they're 56. Not like they're, we, we do things differently. We live our lives differently. And the same is true of addicts. Jay Kopelman: They come to addiction from different places. Not everybody decides they want to just try heroin at a party, and all of a sudden they're addicted. It happens in, in different ways, you know, and the whole fentanyl thing has been so daggum nefarious, right? You know, pushing fentanyl into marijuana. Jay Kopelman: Somebody's smoking a joint and all of a sudden they're addicted to fentanyl or they die. Melissa Lavasani: I think we're having a, Jay Kopelman: it's, it's just not fair to, to say everybody in this pot is the same, or everybody in this one is the same. We have [00:46:00] to look at it differently. Joe Moore: Yeah. I like to zoom one level out and kind of talk about, um, just how hurt we are as a country, as a world really, but as a country specifically, and how many people are out of work for so many. Joe Moore: Difficult reasons and away from their families for so many kind of tragic reasons. And if we can get people back to their families and back to work, a lot of these things start to self-correct, but we have to like have those interventions where we can heal folks and, and get them back. Um, yeah. And you know, everything from trauma, uh, in childhood, you know, adulthood, combat, whatever it is. Joe Moore: Like these things can put people on the sidelines. And Jay, to your point, like you get knee surgery and all of a sudden you're, you know, two years later you're on the hunt for Fentanyl daily. You know, that's tough. It's really tough. Carl Hart does a good job talking about this kind of addiction pipeline and [00:47:00] a few others do as well. Joe Moore: But it's just, you know, kind of putting it in a moral failure bucket. It's not great. I was chatting with somebody about, um, veterans, it's like you come back and you're like, what's gonna make me feel okay right now? And it's not always alcohol. Um, like this is the first thing that made me feel okay, because there's not great treatments and there's, there's a lot of improvements in this kind of like bringing people back from the field that needs to happen. Joe Moore: In my opinion. I, it seems to be shared by a lot of people, but yeah, there's, it's, it's, IGA is gonna be great. It's gonna be really important. I really can't wait for it to be at scale appropriately, but there's a lot of other things we need to fix too, um, so that we can just, you know, not have so many people we need to, you know, spend so much money healing. Joe Moore: Mm-hmm. Jay Kopelman: Yeah. You ahead with that. We don't need the president to sign an executive order to automatically legalize Ibogaine. Right. But it would be nice if he would reschedule it so that [00:48:00] then then researchers could do this research on a larger scale. You know, we could, we could now get some real data that would show the efficacy. Jay Kopelman: And it could be done in a safe environment, you know? And, and so that would be, do Joe Moore: you have any kind of figures, like, like, I've been talking about this for a while, Jay. Like, does it drop the cost a lot of doing research when we deschedule things? Jay Kopelman: I, I would imagine so, because it'll drop the cost of accessing the medicines that are being researched. Jay Kopelman: Right? You, you would have buy-in from more organizations. You know, you might even have a pharma company that comes into this, you know, look at j and j with the ketamine, right? They have, they have a nasal spray version of ketamine that's doing very well. I mean, it's probably their, their biggest revenue [00:49:00] provider for them right now. Jay Kopelman: And, and so. You know, you, it would certainly help and I think, I think it would lower costs of research to have something rescheduled rather than being schedule one. You know it, people are afraid to take chances when you're talking about Schedule one Melissa Lavasani: labs or they just don't have the money to research things that are on Schedule one. Melissa Lavasani: 'cause there's so much in an incredible amount of red tape that you have to go through and, and your facility has to be a certain way and how you contain those, uh, medicines. Oh, researching has to be in a specific container and it's just very cumbersome to research schedule one drugs. So absolutely the cost would go down. Melissa Lavasani: Um, but Joe Moore: yeah, absolutely. Less safes. Melissa Lavasani: Yeah. Joe Moore: Yes. Less uh, Melissa Lavasani: right. Joe Moore: Locked. Yeah. Um, it'll be really interesting when that happens. I'm gonna hold out faith. That we can see some [00:50:00] movement here. Um, because yeah, like why make healing more expensive than it needs to be? I think like that's potentially a protectionist move. Joe Moore: Like, I'm not, I'm not here yet, but, um, look at AbbVie's, uh, acquisition of the Gilgamesh ip. Mm-hmm. Like that's a really interesting move. I think it was $1.2 billion. Mm-hmm. So they're gonna wanna protect that investment. Um, and it's likely going to be an approved medication. Like, I don't, I don't see a world in which it's not an approved medication. Joe Moore: Um, you know, I don't know a timeline, I would say Jay Kopelman: yeah. Joe Moore: Less than six years, just given how much cash they've got. But who knows, like, I haven't followed it too closely. So, and that's an I bga derivative to be clear, everybody, um mm-hmm. If you're not, um, in, in the loop on that, which is hopeful, you know? Joe Moore: Mm-hmm. But I don't know what the efficacy is gonna be with that compared to Ibogaine and then we have to talk about the kind of proprietary molecule stuff. Um, there's like a whole bunch of things that are gonna go on here, and this is one of the reasons why I'm excited about. Federal involvement [00:51:00] because we might actually be able to have some sort of centralized manufacturer, um, or at least the VA could license three or four generic manufacturers per for instance, and that way prices aren't gonna be, you know, eight grand a dose or whatever. Joe Moore: You know, it's, Jay Kopelman: well, I think it's a very exciting time in the space. You know, I, I think that there's the opportunity for innovation. There is the opportunity for collaboration. There's the opportunity for, you know, long-term healing at a very low cost. You know, that we, we have the highest healthcare cost per capita in the world right here in the us. Jay Kopelman: And, and yet we are not the number one health system in the world. So to me, that doesn't add up. So we need to figure out a way to start. Bringing costs down for a lot of people and [00:52:00] at the same time increasing, increasing outcomes. Joe Moore: Absolutely. Yeah. There's a lot of possible outcome improvements here and, and you know, everything from relapse rates, like we hear often about people leaving a clinic and they go and overdose when they get home. Tragically, too common. I think there's everything from, you know, I'm Jay, I'm involved in an organization called the Psychedelics and Pain Association. Joe Moore: We look at chronic pain very seriously, and IGA is something we are really interested in. And if. We could have better, you know, research, there better outcome measures there. Um, you know, perhaps we can have less people on opioids to begin with from chronic pain conditions. Um, Jay Kopelman: yeah, I, I might be due for another Ibogaine journey then, because I deal with chronic pain from Jiujitsu, but, Joe Moore: oh gosh, let's Jay Kopelman: talk Joe Moore: later. Jay Kopelman: That's self inflicted. Some people would say take a month off, but Melissa Lavasani: yeah, Jay Kopelman: I'm [00:53:00] not, I'm not that smart. Joe Moore: Yeah. Um, but you know, this, uh, yeah, this whole thing is gonna be really interesting to see how it plays out. I'm endlessly hopeful pull because I'm still here. Right. I, I've been at this for almost 10 years now, very publicly, and I think we are seeing a lot of movement. Joe Moore: It's not always what we actually wanna see, but it is movement nonetheless. You know, how many people are writing on this now than there were before? Right. You know, we, we have people in New York Times writing somewhat regularly about psychedelics and. Even international media is covering it. What do we have legalization in Australia somewhat recently for psilocybin and MDMA, Czech Republic. Joe Moore: I think Germany made some moves recently. Mm-hmm. Um, really interesting to see how this is gonna just keep shifting. Um Jay Kopelman: mm-hmm. Joe Moore: And I think there's no way that we're not gonna have prescription psychedelics in three years in the United States. It pro probably more like a [00:54:00] year and a half. I don't know. Do you, are you all taking odds? Melissa Lavasani: Yeah. I mean, I think Jay Kopelman: I, I gotta check Cal sheet, see what they're saying. Melissa Lavasani: I think it's safe to say, I mean, this could even come potentially the end of this year, I think, but definitely by the end of 2027, there's gonna be at least one psychedelic that's FDA approved. Joe Moore: Yeah. Yeah. Melissa Lavasani: If you're not counting Ketamine. Joe Moore: Right. Jay Kopelman: I, I mean, I mean it mm-hmm. It, it doesn't make sense that it. Shouldn't be or wouldn't be. Right. The, we've seen the benefits. Mm-hmm. We know what they are. It's at a very low cost, but you have to keep in mind that these things, they need to be done with the right set setting and container. Right. And, and gotta be able to provide that environment. Jay Kopelman: So, but I would, I would love, like I said, I'd love to work myself out of a job here and see this happen, not just for our veterans, [00:55:00] but for everybody. Joe Moore: Mm-hmm. Um, so Melissa, is there a way people can get involved or follow PMC or how can they support your work at PMC? Melissa Lavasani: Yeah, I mean, follow us in social media. Melissa Lavasani: Um, our two biggest platforms are LinkedIn and Instagram. Um, I'm bringing my newsletter back because I'm realizing, um, you know, there is a big gap in, in kind of like the knowledge of Washington DC just in general. What's happening here, and I think, you know, part of PC's value is that we're, we are plugged into conversations that are being had, um, here in the city. Melissa Lavasani: And, you know, we do get a little insight. Um, and I think that that would really quiet a lot of, you know, the, a lot of noise that, um, exists in the, our ecosystem. If, if people just had some clarity on like, what's actually happening or happening here and what are the opportunities and, [00:56:00] um, where do we need more reinforcement? Melissa Lavasani: Um, and, and also, you know, as we're putting together public education campaign, you know. My, like, if I could get everything I wanted like that, that campaign would be this like multi-stakeholder collaborative effort, right? Where we're covering all the ground that we need to cover. We're talking to the patient groups, we're talking to traditional mental health organizations, we're talking to the medical community, we're talking to the general population. Melissa Lavasani: I think that's like another area that we, we just seem to be, um, lacking some effort in. And, you know, ultimately the veteran story's always super compelling. It pulls on your heartstrings. These are our heroes, um, of our country. Like that, that is, that is meaningful. But a lot of the veteran population is small and we need the, like a, the just.[00:57:00] Melissa Lavasani: Basic American living in middle America, um, understanding what psychedelics are so that in, in, in presenting to them the stories that they can relate to, um, because that's how you activate the public and you activate the public and you get them to see what's happening in these clinical trials, what the data's been saying, what the opportunities are with psychedelics, and then they start calling their members of Congress and saying, Hey, there is this. Melissa Lavasani: Bill sitting in Congress and why haven't you signed onto it? And that political pressure, uh, when used the right way can be really powerful. So, um, I think, you know, now we're at this really amazing moment where we have a good amount of congressional offices that are familiar enough with psychedelics that they're willing to move on it. Melissa Lavasani: Um, there's another larger group, uh, that is familiar with psychedelics and will assist and co-sponsor legislation, but there's still so many offices that we haven't been able to get to just 'cause like we don't have all the time in the world and all the manpower in the world to [00:58:00] do it. But, you know, that is one avenue is like the advocates can speak to the, the lawmakers, the experts speak to the lawmakers, and we not, we want the public engaged in this, you know, ultimately, like that's. Melissa Lavasani: Like the best form of harm reduction is having an informed public. So we are not, they're not seeing these media headlines of like, oh, this miracle cure that, um, saved my family. It's like, yes, that can happen psychedelics. I mean, person speaking personally, psychedelics did save my family. But what you miss out of that story is the incredible amount of work I put into myself and put into my mental health to this day to maintain, um, like myself, my, my own agency and like be the parent that I wanna be and be the spouse that I wanna be. Melissa Lavasani: So, um, we, we need to continue to share these stories and we need to continue to collaborate to get this message out because we're all, we're all in the same boat right now. We all want the same things. We want patients to have safe and [00:59:00] affordable access to psychedelic assisted care. Um, and, uh. We're just in the beginning here, so, um, sign up for our newsletter and we can sign up on our website and then follow us on social media. Melissa Lavasani: And, um, I anticipate more and more events, um, happening with PMC and hopefully we can scale up some of these events to be much more public facing, um, as this issue grows. So, um, I'm really excited about the future and I'm, I've been enjoying this partnership with Mission Within. Jay is such a professional and, and it really shows up when he needs to show up and, um, I look forward to more of that in the future. Joe Moore: Fantastic. And Jay, how can people follow along and support mission within Foundation? Jay Kopelman: Yeah, again, social media is gonna be a good way to do that. So we, we are also pretty heavily engaged on LinkedIn and on Instagram. Um, I do [01:00:00] share, uh, a bit of my own stuff as well. On social media. So we have social media pages for Mission within Foundation, and we have a LinkedIn page for mission within foundation. Jay Kopelman: I have my own profiles on both of those as well where people can follow along. Um, one of the other things you know that would probably help get more attention for this is if the general public was more aware of the numbers of professional athletes who are also now pursuing. I began specifically to help treat their traumatic brain injuries and the chronic traumatic encephalopathy that they've, uh, suffered as a result of their time in professional sports or even college sports. Jay Kopelman: And, you know. I people worship these athletes, and I [01:01:00] think that if more of them, like Robert Gall, were more outspoken about these treatments and the healing properties that they've provided them, that it would get even more attention. Um, I think though what Melissa said, you know, I don't wanna parrot anything she just said because she said it perfectly Right. Jay Kopelman: And I'd just be speaking to hear myself talk. Um, but being collaborative the way that we are with PMC and with Melissa is I think, the way to move the needle on this overall. And like she said, if she could get more groups involved in, in these discussions, it would, it would do wonders for us. Joe Moore: Well, thank you both so much for your hard work out there. I always appreciate it when people are showing up and doing this important, [01:02:00] sometimes boring and tedious, but nevertheless sometimes, sometimes exciting work. And um, so yeah, just thank you both and thank you both for showing up here to psychedelics today to join us and I hope we can continue to support you all in the future. Jay Kopelman: Thank you, Joe. Thank you, Joe. It's a pleasure being with you today and with Melissa, of course, always Melissa Lavasani: appreciate the time and space. Joe Moore: Thanks.  

Send a textGene regulation through RNAs, the neurobiology of opioid addiction, and how psychedelics affect drug-seeking by modulating inflammation and plasticity. Not medical advice.TOPICS DISCUSSED:Gene regulation basics: DNA transcribes to RNAs, including non-coding types like microRNAs that inhibit mRNA translation into proteins, influencing up to 60% of the proteome.Non-coding RNAs in neuroplasticity: MicroRNAs and circular RNAs regulate synaptic changes, with activity-induced ones like miR-485-5p linked to rapid responses in drug cue memory and addiction reinforcement.Opioid addiction models: Rats self-administer heroin or fentanyl via levers, showing compulsive seeking; fentanyl's higher potency drives faster learning but similar long-term effects to heroin when doses are equated.Differences between opioids: Heroin and fentanyl both activate mu-opioid receptors for euphoria and dopamine release, but fentanyl lingers longer; no major behavioral differences in seeking once potency is matched.Psilocybin's effects on addiction: A single psilocybin dose post-abstinence reduces heroin-seeking in rats by dampening neuroinflammation in brain regions like the nucleus accumbens and prefrontal cortex.Brain Inflammation: Opioids induce pro-inflammatory changes via cytokines like IL-17A and pathways like TNF-alpha, leading to glial activation and blood-brain barrier leaks; psilocybin counters this.MicroRNA biomarkers: Blood microRNAs reflect gene expression patterns tied to disease states, with potential to predict opioid relapse risk, treatment response, or neonatal withdrawal severity non-invasively.Future research: Ongoing work links psilocybin's serotonin 2A activation to anti-inflammatory gene changes, plus human studies on microRNAs for personalized addiction treatments.ABOUT THE GUEST: Stephanie Daws, PhD is an associate professor at Temple University in the Center for Substance Abuse Research and Department of Neurosciences, where she researches mechanisms of drug-seeking behavior with a focus on opioids and psychedelics.RELATED EPISODE:M&M 2 | Psilocybin, LSD, Ketamine, InflamSupport the showHealth Products by M&M Partners: SporesMD: Premium mushrooms products (gourmet mushrooms, nootropics, research). Use code 'nickjikomes' for 20% off. Lumen device: Optimize your metabolism for weight loss or athletic performance. MINDMATTER gets you 15% off. AquaTru: Water filtration devices that remove microplastics, metals, bacteria, and more from your drinking water. Through link, $100 off AquaTru Carafe, Classic & Under Sink Units; $300 off Freestanding models. Seed Oil Scout: Find restaurants with seed oil-free options, scan food products to see what they're hiding, with this easy-to-use mobile app. KetoCitra—Ketone body BHB + electrolytes formulated for kidney health. Use code MIND20 for 20% off any subscription (cancel anytime) For all the ways you can support my efforts

What happens when a 20 year mental health veteran has her own existential crisis then undergoes her own psychedelic therapy? In Inna Zelikman's case, it completely transformed how she practices medicine.Inna Zelikman, RN, MS, ANP, PMH-NP, is the Director of Integrative Mental Health at Recovery Without Walls and a MAPS certified MDMA practitioner. Five years ago, her own psychedelic healing journey changed everything about how she sees and treats patients. Now she's challenging the cookie cutter protocols that dominate our field in favor of what she calls an "organic" approach to treatment.In this conversation, Inna shares her comprehensive patient assessment strategies, the medication categories that secretly block healing (even though they're not contraindications), and why some patients have profound psychedelic experiences but can still struggle.From consulting with psilocybin centers in Oregon to treating ketamine addiction, Inna offers a nuanced perspective on the complexities of psychedelic medicine and why proper preparation, support, and integration actually matter for lasting results.What You'll Learn:

Send a textSchedule an Rx AssessmentRapid growth is exciting but without the right metrics, culture, and plan, it can quietly put your pharmacy at risk.In this episode, Scotty Sykes, CPA, CFP®, Bonnie Bond, CPA, MBA, and Austin Murray sit down with Jim Hrncir, R. Ph. FACP, Owner of Las Colinas Compounding Pharmacy and Wellness Center veteran compounding pharmacist and owner, to unpack what it really takes to run a sustainable compounding pharmacy through industry cycles, GLP-1 volatility, and ownership transitions.We cover:The KPIs Jim actually tracks to manage a complex compounding operationWhy cash position may be the most overlooked metric in pharmacyHow GLP-1s changed the business—and why diversification still mattersInternal succession vs. private equity: the real tradeoffsAnd more!More About Our Guest:Jim Hrncir RPh and wife Jan founded Las Colinas Pharmacy, Compounding & Wellness in 1984. Recognized as one of the pioneers of modern pharmaceutical compounding, Jim's 1986 creation of Estradiol Transdermal Gel was the first of its kind in the United States. He is responsible for the formulation of many Bio-Identical Hormone, Dermatological, Nutritional, and Anti-Aging compounds in wide use throughout the United States. Jim was named the 2017 Compounding Pharmacist of the Year by Professional Compounding Centers of America (PCCA) and is a Fellow of the Alliance for Pharmacy Compounding (FAPC). NCPA's magazine America's Pharmacist featured Jim and Las Colinas Pharmacy as the cover story for December 2018.Jim has received extensive continuing education in the areas of Bio-Identical Hormones, Nutrition, Anti-Aging Medicine, Weight Management, Pain Management, Neurotransmitter Management, Natural and Functional Medicine including the use of botanical medicines, nutritional supplements, Detoxification and Purification, homeopathy and lab testing. He has lectured across the country on a variety of topics including Clinical Patient Consulting, BHRT Assessment and Case Management, Low Dose Naltrexone, Traumatic Brain Injury Treatment Protocols, and Ketamine for Treatment-Resistant Depression and PTSD.Jim is a member of Professional Compounding Centers of America (PCCA), American Academy of Anti-Aging Medicine, Age Management Medical Group, Texas Pharmaceutical Association, Alliance for Pharmacy Compounding, and the National Association of Community Pharmacists.Stay connected with Jim and Las Colinas Pharmacy: Jim's LinkedInLas Colinas Pharmacy WebsiteLas Colinas Pharmacy FacebookLas Colinas Pharmacy TikTokLas Colinas Pharmacy InstagramLas Colinas Pharmacy LinkedInStay connected with us: FacebookYouTube LinkedInInstagram More resources on this topic: Podcast - Driving Independent Pharmacy Profitability in 2026Podcast – The Startup Compounding Pharmacy Playbook

Welcome to Part 6 of the Lucy in the Sky with Dinahs series where Natasha discusses psychedelic-assisted therapy within high-demand religious context of Sexual and Religious Trauma. Natasha is joined by Amy Rossi and Aimee Heffernan. In this episode, the team discusses ketamine. Note that neither Natasha or the Amie's are doctors. They do not condone illegal behavior. Please make sure you know your local and state laws before using psychedelics. For more on Amy Rossi, you can go to her instagram at @messages.from.the.medicine For more on Amy Heff, she has an office in Bountiful, Utah, and does video consulting. She's on instagram at: @aimeeheff   To help keep this podcast going, please consider donating at natashahelfer.com and share this episode. To watch the video of this podcast, you can subscribe to Natasha's channel on Youtube and follow her professional Facebook page at natashahelfer LCMFT, CST-S. You can find all her cool resources at natashahelfer.com.  The information shared on this program is informational and should not be considered therapy. This podcast addresses many topics around mental health and sexuality and may not be suitable for minors. Some topics may elicit a trigger or emotional response so please care for yourself accordingly. The views, thoughts and opinions expressed by our guests are their own and do not necessarily reflect the views or feelings of Natasha Helfer or the Natasha Helfer Podcast. We provide a platform for open and diverse discussions, and it is important to recognize that different perspectives may be shared. We encourage our listeners to engage in critical thinking and form their own opinions. The intro and outro music for these episodes is by Otter Creek. Thank you for listening. And remember: Symmetry is now offering Ketamine services. To find out more, go to symcounseling.com/ketamine-services. There are also several upcoming workshops. Visit natashahelfer.com or symcounseling.com to find out more.

Enamory is a clinical practice, training institute, and nonprofit research organization focused on psychedelic assisted couples therapy. In this episode, clinical psychologists Chandra Kian and Kayla Knopp discuss their work integrating ketamine assisted psychotherapy with evidence based couples therapy models. Both guests trained as academic researchers at the University of California San Diego Veterans Affairs system, where they worked on large scale couples based PTSD trials. They later co founded Enamory to continue clinical work, train therapists, and conduct research focused specifically on relationships. Early Themes in Enamory and Couples Therapy The conversation begins with Dr. Kian and Dr. Knopp describing their background in couples based PTSD research and how that work shaped their clinical approach. They explain how existing couples therapy models often stall when partners cannot soften, access vulnerability, or understand each other's internal experience. Their early exposure to MDMA assisted therapy research highlighted how psychedelic states can temporarily reduce defensiveness and rigid narratives.

Claude contre ChatGPT, la promesse d’Elon Musk pour des data centers dans l’espace, compétition entre Claude Opus 4.6 et GPT 5.3 Codex, pubs du Super Bowl, IA qui socialisent, et les promesses de GTA 6.  Me soutenir sur Patreon Me retrouver sur YouTube On discute ensemble sur Discord Cote Cote Codex Photofinish pour Anthropic et Open AI, qui gagne la course de la hype ? Ça y est, l'IA est la nouvelle crypto (.com). Sam Altman égratigné par les mamans cougars. Pas assez cher mon fils ! Qui gagne la course du pognon ? Homard d'alors : le débat sur la sécurité loin d'être Claw… Pruneau d'agent : 4claw, Moltroad, Rentahuman, Moltmatch, Moltbunker, SpaceMolt et Molthub ! Ketamine de rien… Le million ! Le million ! Elon parfaitement sérieux avec ses space datacenters. Mais ça risque de pas être si simple. Né sous X : un algorithme pas si transparent que ça… Dead see scrolls : TikTok est trop addictif pour l'UE. Procès à l'appel : Google et le département de la justice font un crossover. Jeux vidéo GTA 6 bientôt interdit en France ? Non. Record pour la Switch, pas pour la Xbox… Et pour la Gabecube?! Participants Une émission préparée par Guillaume Poggiaspalla Présenté par Guillaume Vendé

Let us know what you think! Text us!Christi Myers joins Deny Caballero to discuss ketamine therapy, trauma healing, and the role of mindfulness and integration in modern mental health care. This episode explores safety, access, and the future of psychedelic medicine.Key Topics:Ketamine therapyTrauma and mental healthMindfulness and breathworkPsychedelic medicineHealing and integration

What if your best days haven't even happened yet? In this episode of Ask Kati Anything, I'm joined by the incredible Amy Edwards—CEO, author, and host of The Amy Edwards Show. At 53, Amy is the happiest she's ever been, but getting here required walking through some of life's darkest valleys. We dive deep into the messy, complicated, and ultimately beautiful process of transformation. Amy opens up about the stigma of being twice-divorced, the "blackout" period of losing her voice during a legal battle, and her unconventional journey through psychedelic healing and sobriety. Whether you are struggling with a "failed" relationship, feeling stuck in a cycle of rumination, or wondering if it's too late to start over, this conversation is a reminder that you don't need anything outside of yourself to access hope. Shopping with our sponsors helps support Ask Kati Anything. Please check out this week's special offer: Feel like your best self again, visit https://www.forhers.com/KATI to get a personalized, affordable plan that gets you! Chapters 00:00 – Meet Amy Edwards 03:04 – Becoming the "Matriarchs" after losing parents 04:29 – Religious differences and choosing love over judgment 09:35 – The reality of divorce at 25 vs. later in life 13:57 – A perfect storm: Pregnancy, losing a mother, and a broken leg 17:46 – The "Rebound Marriage" and learning to stand up for yourself 21:14 – Why "Staying for the Kids" can be the real failure 26:42 – Modeling resilience: Showing children that women can do anything 30:12 – Mental health tools: The "Don't Drink the Drano Today" logic 36:32 – Psychedelics and Ego Death: Rewiring the brain 40:32 – Ketamine therapy and clearing the "ruminating sand" 43:10 – The road to sobriety and finding a growth-mindset partner 54:19 – The "Table" Metaphor: Breaking the cycle of transactional love 01:03:16 – Losing your voice: When the body forces you to slow down 01:07:37 – Radical Self-Love: doing mirror work 01:15:45 – Your best days haven't happened yet MORE AMY https://www.youtube.com/@TheAmyEdwardsShow The Trouble with Becoming a Witch: A Novel by Amy Edwards https://amzn.to/4ahkoFU https://www.instagram.com/realamyedwards/ MY BOOKS Why Do I Keep Doing This? https://geni.us/XoyLSQ Traumatized https://geni.us/Bfak0j Are u ok? https://geni.us/sva4iUY ONLINE THERAPY (enjoy 10% off your first month) While I do not currently offer online therapy, BetterHelp can connect you with a licensed, online therapist: https://betterhelp.com/kati PARTNERSHIPS Nick Freeman | nick@biglittlemedia.co DISCLAIMER The information provided in this video is for educational and informational purposes only and is not intended as medical or mental health advice. It should not be used to diagnose or treat any health problem or disease. Always consult with a qualified healthcare professional for diagnosis and treatment. Viewing this content does not establish a therapist-client relationship. Ask Kati Anything ep. 300 | Your mental health podcast, with Kati Morton, LMFT Learn more about your ad choices. Visit megaphone.fm/adchoices

Fergie's big pimpin' with Epstein and the files; Ketamine, then and now.

Natasha is joined by Katherine Spearing, MA, CTRC, to discuss her latest book, "A Thousand Tiny Paper Cuts," which addresses the spiritual abuse survivor's recovery journey, on this episode of the Natasha Helfer Podcast. Katherine Spearing MA, CTRC is the founder of Tears of Eden (https://www.tearsofeden.org/), a nonprofit supporting survivors of spiritual abuse, and the former executive producer and host of the groundbreaking podcast "Uncertain", a podcast that pioneered pivotal conversations around Spiritual Abuse. She's also a Certified Trauma Recovery Practitioner (https://www.katherinespearing.com/coaching) working primarily with women who have been impacted by the patriarchy and artists navigating religious trauma. Katherine is a huge advocate for the power of art to help us on our healing journey. She participates in improv theater both as a performer and coach and is the author of one novel ("Hartfords" https://www.katherinespearing.com/books).  She has been a guest on a number of podcasts, including "IndoctriNation" and "A Little Bit Culty," is the author of several nonfiction articles, and writes regularly at katherinespearing.com and tearsofeden.org. Sign up for the newsletter at her website:  katherinespearing.com You can purchase her book at the link below: https://amzn.to/49J7OAs   To help keep this podcast going, please consider donating at natashahelfer.com and share this episode. To watch the video of this podcast, you can subscribe to Natasha's channel on Youtube and follow her professional Facebook page at natashahelfer LCMFT, CST-S. You can find all her cool resources at natashahelfer.com.  The information shared on this program is informational and should not be considered therapy. This podcast addresses many topics around mental health and sexuality and may not be suitable for minors. Some topics may elicit a trigger or emotional response so please care for yourself accordingly. The views, thoughts and opinions expressed by our guests are their own and do not necessarily reflect the views or feelings of Natasha Helfer or the Natasha Helfer Podcast. We provide a platform for open and diverse discussions, and it is important to recognize that different perspectives may be shared. We encourage our listeners to engage in critical thinking and form their own opinions. The intro and outro music for these episodes is by Otter Creek. Thank you for listening. And remember: Symmetry is now offering Ketamine services. To find out more, go to symcounseling.com/ketamine-services. There are also several upcoming workshops. Visit natashahelfer.com or symcounseling.com to find out more.

In this episode, I sit down with Dr. Michael Ziffra, a psychiatrist and associate professor at Northwestern University who specializes in anxiety disorders. Dr. Ziffra has been writing a Substack series called "Wise Mind in Anxious Times," exploring how we can better navigate the intersection of mental health and our turbulent political landscape.We begin by discussing the alarming advice that made headlines—a Yale psychiatrist suggesting people should avoid family members who voted differently than them. Dr. Ziffra and I unpack why avoidance is the exact opposite of what we'd normally recommend for anxiety, and how vilifying language creates a vicious cycle that intensifies fear and paranoia. He offers practical wisdom on how softening our language can open doors to genuine dialogue.From there, we dive deep into the world of psychiatric medication. Dr. Ziffra helps demystify the "chemical imbalance" theory, explaining why "dysfunction" is a better term than "imbalance" since we can't actually measure neurotransmitter levels the way we can check vitamin D. We explore fascinating territory including opioid receptors and depression, how low-dose naltrexone works, the dangers of chronic benzodiazepine use, and why tapering off medications requires far more patience than most people realize. We also discuss the overlooked impacts of birth control on young women's mental health, sleep disorders that masquerade as psychiatric conditions, and the emerging questions around weight loss drugs and ketamine for treatment-resistant depression.Dr. Michael Ziffra is a psychiatrist and Associate Professor at Northwestern University, specializing in anxiety and mood disorders. Dr. Ziffra also is the author of “Wise Mind in Anxious Times”, a series on Substack exploring the interface between mental health and our sociopolitical climate. Its aim is to provide analysis and commentary from a mental health specialist with insight into why we experience anxiety about particular issues and happenings, and how to better manage that anxiety. Follow him on Substack, X, or Instagram.[00:00:00] Start[00:00:40] Guest Introduction: Dr. Michael Ziffra[00:02:28] Yale Psychiatrist's Bad Advice on Family[00:09:39] What Does a Psychiatrist Actually Do?[00:12:03] The Chemical Imbalance Theory Explained[00:18:02] Low-Dose Naltrexone and Opioid Receptors[00:23:27] Benzodiazepines: Dangers and Dependence[00:31:00] Safe Medication Tapering Strategies[00:38:29] Nicotine Addiction and Smoking Cessation[00:43:15] Psychiatry Beyond Just Medication[00:47:30] Birth Control and Mental Health[00:51:47] Sleep Disorders That Mimic Depression[00:55:01] Weight Loss Drugs: Psychological Effects[01:00:52] Ketamine for Treatment-Resistant Depression[01:12:06] Where to Find Dr. ZiffraROGD REPAIR Course + Community gives concerned parents instant access to over 120 lessons providing the psychological insights and communication tools you need to get through to your kid. Now featuring 24/7 personalized AI support implementing the tools with RepairBot! Use code SOMETHERAPIST2025 to take 50% off your first month.PODCOURSES: use code SOMETHERAPIST at LisaMustard.com/PodCoursesTALK TO ME: book a meeting.PRODUCTION: Looking for your own podcast producer? Visit PodsByNick.com and mention my podcast for 20% off your initial services.SUPPORT THE SHOW: subscribe, like, comment, & share or donate.Watch NO WAY BACK: The Reality of Gender-Affirming Care. Use code SOMETHERAPIST to take 20% off your order.MUSIC: Thanks to Joey Pecoraro for our song, “Half Awake,” used with gratitude & permission. ALL OTHER LINKS HERE. To support this show, please leave a rating & review on Apple, Spotify, or wherever you get your podcasts. Subscribe, like, comment & share via my YouTube channel. Or recommend this to a friend!Learn more about Do No Harm.Take $200 off your EightSleep Pod Pro Cover with code SOMETHERAPIST at EightSleep.com.Take 20% off all superfood beverages with code SOMETHERAPIST at Organifi.Check out my shop for book recommendations + wellness products.Show notes & transcript provided with the help of SwellAI.Special thanks to Joey Pecoraro for our theme song, “Half Awake,” used with gratitude and permission.Watch NO WAY BACK: The Reality of Gender-Affirming Care (our medical ethics documentary, formerly known as Affirmation Generation). Stream the film or purchase a DVD. Use code SOMETHERAPIST to take 20% off your order. Follow us on X @2022affirmation or Instagram at @affirmationgeneration.Have a question for me? Looking to go deeper and discuss these ideas with other listeners? Join my Locals community! Members get to ask questions I will respond to in exclusive, members-only livestreams, post questions for upcoming guests to answer, plus other perks TBD. ★ Support this podcast on Patreon ★

Welcome back to February's Papers of the Month! We start this month looking a the right place to perform a prehospital anaesthetic. Traditionally we've been taught it should be somewhere with 360-degree access to allow the greatest safety, which means intubating in an ambulance and other locations are a no-go. But does it actually reduce complications, and what about other locations and situations? This paper explores whether location is associated with outcomes, or whether it might actually be a reasonable and sometimes advantageous to forgo that 360 access. We've talked a lot about pad position in cardiac arrest recently, mainly in the context of DSD, but what about initial pad position? Our second paper may be even more important than DSD! This one takes a look at initial pad position, antero–lateral versus antero–posterior placement and asks whether initial pad position influences return of spontaneous circulation. Finally, we take on one of the most debated topics in emergency and critical care airway management, with choice of induction agent. We look at a brilliant RCT which compares Etomidate to Ketamine and their haemodynamic stability. This one challenges some widely held assumptions, in an attempt to provide some much-needed clarity in what we should be using. Once again we'd love to hear any thoughts or feedback either on the website or via X @TheResusRoom! Simon & Rob

Tara Olson joins Natasha on this episode of the Natasha Helfer Podcast. They discuss the intersection of eating disorders, religion and sex. Tara Olson is an Associate Certified Social Worker (CSW) who approaches therapy from a feminist-multicultural, trauma-informed, and culturally responsive framework. She views healing as a collaborative process, where clients bring their lived wisdom and cultural expertise, and together, client and therapist co-create a space for growth and change. For more on Tara, go here: https://symcounseling.com/tara-olson/ Natasha is doing an Ethical Nonmonogamy group starring February 24th. For more, go here: https://symcounseling.com/navigating-ethical-non-monogamy/ To help keep this podcast going, please consider donating at natashahelfer.com and share this episode. To watch the video of this podcast, you can subscribe to Natasha's channel on Youtube and follow her professional Facebook page at natashahelfer LCMFT, CST-S. You can find all her cool resources at natashahelfer.com.  The information shared on this program is informational and should not be considered therapy. This podcast addresses many topics around mental health and sexuality and may not be suitable for minors. Some topics may elicit a trigger or emotional response so please care for yourself accordingly. The views, thoughts and opinions expressed by our guests are their own and do not necessarily reflect the views or feelings of Natasha Helfer or the Natasha Helfer Podcast. We provide a platform for open and diverse discussions, and it is important to recognize that different perspectives may be shared. We encourage our listeners to engage in critical thinking and form their own opinions. The intro and outro music for these episodes is by Otter Creek. Thank you for listening. And remember: Symmetry is now offering Ketamine services. To find out more, go to symcounseling.com/ketamine-services. There are also several upcoming workshops. Visit natashahelfer.com or symcounseling.com to find out more.

Listen without ads at:www.patreon.com/dopeypodcastThis Week on The Wednesday Dose of Dopey!Dave kicks off this Wednesday Dose solo from his dad's house, riffing on nostalgic broke-addict snacks (Little Debbie oatmeal pies as cheap highs) and weird fridge finds, before diving into fan Spotify comments praising last week's emotional Erin Khar episode. He shares wild Miles Davis coke-paranoia excerpts from the autobiography (Ferrari abandonment, trash-room hiding, dealer tricks), and recommending Kind of Blue and In a Silent Way as sick sick records!Then we welcome Sandra Vergara (Selling Sunset star, Sofia Vergara's cousin/sister-figure). Sandra opens up about a traumatic Colombian childhood: brother's murder at age 9, raised by an aunt after her bio-mom's brain damage left her mentally stuck at 12, feeling like a "burden," early glue-sniffing experiment, near-fatal ruptured appendix/septic shock at 16, and constant walking-on-eggshells survival via art, empathy, and never taking abuse personally.In LA from 18, she dabbled in makeup/acting (Fright Night), when she began drinking heavy. Blackouts, self-harm (throwing herself through glass), and suicide ideation. followed. First rehab in Medellín (befriended staff for special treatment → false security). Post-rehab: mushrooms sparked a "psychedelic love" fling, ayahuasca faced childhood trauma head-on, but led to half-assed AA and relapses.COVID alone-time in NYC brought painting growth, but cat Stewie's death (worse than losing family) plunged her into deep  depression. Enter ketamine: started therapeutic (Mindbloom) but escalated to daily K-holes with Oculus VR for near-death/grief escapes, addictive Journey Circle weekends (MDMA/ayahuasca/mushrooms group catharsis without integration), erratic calls to mom, club blackouts, and cousin finding her passed out. Family intervention (Sophia pays, nephew packs her) lands her in trauma-focused Breathe Life rehab.She firmly rejects "California sober" as a trap—psychedelics delayed real surrender for her; true addicts can't substitute one mind-alter for another. Full AA commitment (no more a la carte) + Kabbalah (post-breakup desperation) changed everything: tikkun (soul correction via tough life choices), turning reactive impulses (anger/gossip) into proactive restriction, daily study/meditation for frequency shifts. Ties Kabbalah to quantum physics (observer effect = perception shapes reality, entanglement = we're all connected, certainty in the unknown = surrender).Sandra discusses Selling Sunset challenges (producer manipulation, ego, glamour vs. spiritual presence) and her new neuroscience/IFS/Kabbalah coaching for holistic recovery (mind stories, body regulation, spirit alignment). All that and much more on the brand new episode of that good old dopey show!  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Join us for this episode which is a fast, honest tour through what ketamine can actually do for mental health—without the hype. We sit down with addiction psychiatrist Dr. Mark Hrymoc to unpack where the evidence is strongest, who qualifies, and why IV ketamine often produces quicker relief than nasal esketamine when depression won't budge. From treatment-resistant depression and acute suicidality to anxiety and PTSD, we dig into the protocols that matter: six-session inductions, customized maintenance, and practical strategies for measuring progress with tools like the PHQ-9.We pull back the curtain on how ketamine works at the receptor level—NMDA antagonism, downstream dopamine effects, and BDNF-driven neuroplasticity—and explain why dissociation may help some patients but isn't required for benefit. You'll hear how we screen candidates, manage blood pressure, reduce nausea, and set up sessions with eye masks, ambient music, and a nurse at the bedside so the experience is safe, focused, and grounded. We also get real about addiction risk, clarifying the difference between recreational use and a carefully monitored medical protocol, and how stable recovery timelines factor into clinical decision-making.For PTSD and anxiety, we explore pairing ketamine with psychotherapy and post-session integration to turn insights into change. We compare IV ketamine's dosing flexibility with Spravato's structured pathway, talk costs and coverage, and outline how to taper other meds only after sustained stability. Looking ahead, we spotlight promising research directions—from extending response with adjuncts to early signals for substance use disorders—and why interventional psychiatry is opening a much-needed chapter beyond traditional antidepressants. If you've wondered whether ketamine is a bridge or a destination, this conversation gives you a clear, practical map. Subscribe, share with a clinician friend, and leave a review to help others find evidence-based mental health care.To contact Dr. Grover - ammadeasy@fastmail.com

In this powerful and timely conversation, Emily sits down with Conscious Ketamine Coach Bronwyn Davis to explore the healing potential of ketamine therapy, especially when paired with conscious integration.Whether you're ketamine-curious or already exploring alternative healing, this episode breaks down the why and how behind using ketamine in a safe, supportive, and transformational way.We talk about:The difference conscious integration makesThe benefits of working with ketamine especially for high performersWho might benefit from this modality (and how to know if it's aligned)What to look for in a good ketamine experience for yourselfBronwyn brings 20+ years of experience coaching high performers, and the benefits they're experiencing going forward with the ketamine experience.To learn more about Bronwyn's work: https://www.bronwyndavis.com/For Emily's current offerings: https://emilymarie.com/offerings/

As 2026 gets underway we know that many take time around this new beginning to improve not only their physical, but also their mental health. With that in mind, we're rerunning an episode with Leanne Williams on the future of depression care. Leanne is an expert on clinical depression and is working on new ways to more precisely diagnose depression in order to develop more effective treatment. For anyone who has suffered from depression or knows someone who has, it's an episode that provides hope for what's on the horizon. We hope you'll take another listen and also share this episode with anyone who you think may benefit from the conversation. Episode Reference Links:Stanford Profile: Leanne WilliamsConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Leanne Williams, a professor of Psychiatry and Behavioral Science at Stanford University.(00:01:43) What Is Depression?Distinguishing clinical depression from everyday sadness.(00:03:31) Current Depression Treatment ChallengesThe trial-and-error of traditional depression treatments and their timelines.(00:06:16) Brain Mapping and Circuit DysfunctionsAdvanced imaging techniques and their role in understanding depression.(00:09:03) Diagnosing with Brain ImagingHow brain imaging can complement traditional diagnostic methods in psychiatry.(00:10:22) Depression BiotypesIdentifying six distinct biotypes of depression through brain imaging.(00:12:31) Cognitive Features of DepressionHow cognitive impairment plays a major role in certain depression biotypes.(00:14:11) Matching Treatments to BiotypesFinding appropriate treatments sooner using brain-based diagnostics.(00:15:38) Expanding Treatment OptionsPersonalizing therapies and improving treatment outcomes based on biotypes.(00:19:03) AI in Depression TreatmentUsing AI to refine biotypes and predict treatment outcomes with greater accuracy.(00:22:15) Psychedelics in Depression TreatmentThe potential for psychedelic drugs to target specific biotypes of depression.(00:23:46) Expanding the Biotypes FrameworkIntegrating multimodal approaches into the biotype framework.(00:27:29) Reducing Stigma in DepressionHow showing patients their brain imaging results reduces self-blame and stigma.(00:29:38) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This Week on The Wednesday Dose of Dopey!Dave kicks off this Wednesday Dose solo from his dad's house, riffing on nostalgic broke-addict snacks (Little Debbie oatmeal pies as cheap highs) and weird fridge finds, before diving into fan Spotify comments praising last week's emotional Erin Khar episode. He shares wild Miles Davis coke-paranoia excerpts from the autobiography (Ferrari abandonment, trash-room hiding, dealer tricks), and recommending Kind of Blue and In a Silent Way as sick sick records!Then we welcome Sandra Vergara (Selling Sunset star, Sofia Vergara's cousin/sister-figure). Sandra opens up about a traumatic Colombian childhood: brother's murder at age 9, raised by an aunt after her bio-mom's brain damage left her mentally stuck at 12, feeling like a "burden," early glue-sniffing experiment, near-fatal ruptured appendix/septic shock at 16, and constant walking-on-eggshells survival via art, empathy, and never taking abuse personally.In LA from 18, she dabbled in makeup/acting (Fright Night), when she began drinking heavy. Blackouts, self-harm (throwing herself through glass), and suicide ideation. followed. First rehab in Medellín (befriended staff for special treatment → false security). Post-rehab: mushrooms sparked a "psychedelic love" fling, ayahuasca faced childhood trauma head-on, but led to half-assed AA and relapses.COVID alone-time in NYC brought painting growth, but cat Stewie's death (worse than losing family) plunged her into deep  depression. Enter ketamine: started therapeutic (Mindbloom) but escalated to daily K-holes with Oculus VR for near-death/grief escapes, addictive Journey Circle weekends (MDMA/ayahuasca/mushrooms group catharsis without integration), erratic calls to mom, club blackouts, and cousin finding her passed out. Family intervention (Sophia pays, nephew packs her) lands her in trauma-focused Breathe Life rehab.She firmly rejects "California sober" as a trap—psychedelics delayed real surrender for her; true addicts can't substitute one mind-alter for another. Full AA commitment (no more a la carte) + Kabbalah (post-breakup desperation) changed everything: tikkun (soul correction via tough life choices), turning reactive impulses (anger/gossip) into proactive restriction, daily study/meditation for frequency shifts. Ties Kabbalah to quantum physics (observer effect = perception shapes reality, entanglement = we're all connected, certainty in the unknown = surrender).Sandra discusses Selling Sunset challenges (producer manipulation, ego, glamour vs. spiritual presence) and her new neuroscience/IFS/Kabbalah coaching for holistic recovery (mind stories, body regulation, spirit alignment). All that and much more on the brand new episode of that good old dopey show!  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Quintin Hunt joins Natasha on this episode of the Natasha Helfer Podcast. They discuss a difficult topic: preventing suicide. More on Dr. Hunt: My journey towards being a therapist began when I was 8 years old: my oldest brother died by suicide, my youngest brother developed schizophrenia, and I was sexually abused. It was then, at 8, my own suicidal thoughts began. Throughout my adolescence and early adulthood I struggled with deep feelings of depression, that no one could ever love me, and that even my feelings and emotions did not matter. I even felt God hated me because of the trauma I had gone through and more because of who I was attracted to. The only way I knew how to receive some pieces of love and acceptance I deeply desire was to hid myself and my feelings from everyone around me. My trauma, my family's trauma, and our struggles to get help that helped us deal with OUR patterns of generational trauma is what pushed me towards doctoral education (PhD) and studying what makes someone suicidal and how to help the process of suicide bereavement. It was through this process of studying suicidality over nearly two decades that I was finally able to see the patterns of generational trauma many suicidal folks live in—and I was finally able to see the patterns of generational trauma in my own life and how my own compulsion to hide myself perpetuated the patterns of self-hatred, depression, and loneliness. Identifying the patterns of trauma in my life allowed me to believe that I did not deserve my trauma, that my emotions mattered, and that I mattered. I was finally able to advocate for myself and have been able to finally, for the first time to develop friendships and accept love that others were willing to offer but I was unable to see. You can check out more information at his practice: Olive View Therapy: https://www.oliveviewtherapy.com   To help keep this podcast going, please consider donating at natashahelfer.com and share this episode. To watch the video of this podcast, you can subscribe to Natasha's channel on Youtube and follow her professional Facebook page at natashahelfer LCMFT, CST-S. You can find all her cool resources at natashahelfer.com.  The information shared on this program is informational and should not be considered therapy. This podcast addresses many topics around mental health and sexuality and may not be suitable for minors. Some topics may elicit a trigger or emotional response so please care for yourself accordingly. The views, thoughts and opinions expressed by our guests are their own and do not necessarily reflect the views or feelings of Natasha Helfer or the Natasha Helfer Podcast. We provide a platform for open and diverse discussions, and it is important to recognize that different perspectives may be shared. We encourage our listeners to engage in critical thinking and form their own opinions. The intro and outro music for these episodes is by Otter Creek. Thank you for listening. And remember: Symmetry is now offering Ketamine services. To find out more, go to symcounseling.com/ketamine-services. There are also several upcoming workshops. Visit natashahelfer.com or symcounseling.com to find out more.

PJ talks to addiction counsellor Michael Guerin and drug awareness activist Bernard O'Hehir about the risks many on the drugs are not even aware of that have tragic and embarrassing consequences Hosted on Acast. See acast.com/privacy for more information.

PJ Coogan hears how Farranree residents defended the trees they grew up with, chatted about the best horror films and why we terrify ourselves watching them, learns who Ketamine is flooding Cork and destroys people who use it. And more... Hosted on Acast. See acast.com/privacy for more information.

Singer-songwriter and Lyme disease advocate Jesse Ruben joins the Tick Boot Camp Podcast for an incredibly honest, emotional, and deeply educational conversation about chronic Lyme disease, identity loss, treatment failure, unconventional healing, relapse, nervous system trauma, and the role of music and community in survival. Jesse's journey spans more than a decade and includes misdiagnosis, years of antibiotic treatment, experimental therapies, remission, relapse during the pandemic, gut microbiome restoration, nervous system healing, and ultimately a renewed sense of purpose through advocacy and art. This episode is essential listening for anyone navigating chronic Lyme disease, supporting someone who is sick, or questioning whether healing is still possible. Jesse Ruben's Early Life and Music Career Jesse grew up outside Philadelphia, surrounded by music, creativity, and curiosity. While he jokes that his songwriting degree was “a very expensive, useless piece of paper,” the competitive creative environment of music school helped sharpen his storytelling voice. By his early 20s, Jesse was living in New York City, touring, running marathons, and building momentum as an independent musician. He had just completed his third New York City Marathon, was in peak physical condition, and his career was accelerating—until his health began to unravel. The Onset of Illness: When Lyme Disease Took Everything Jesse's first red flag appeared when he became short of breath climbing subway stairs, despite being a marathon runner. Soon after, nausea, dizziness, headaches, neurological symptoms, and crushing fatigue followed. On Christmas Day 2012, Jesse developed what seemed like a flu that never went away. Over the following months, symptoms escalated dramatically: Severe fatigue that made basic movement impossible Brain fog and memory loss Crawling sensations under the skin Air hunger and dizziness Anxiety, depression, and mood changes Weight loss and neurological dysfunction Despite seeing 15 doctors over nine months, Jesse received conflicting diagnoses ranging from vitamin deficiencies to fibromyalgia and lupus. Every test came back “normal.” Insurance denied coverage. Doctors told him he would “have to live with it.” During a national tour, Jesse was so debilitated that a friend physically lifted him onto the stage to perform, then carried him back to the van afterward. Eventually, through relentless self-research, Jesse discovered a symptom list online that finally connected the dots: Lyme disease. Diagnosis and Early Treatment Failure Jesse was ultimately diagnosed at the Morrison Center in New York City, where testing confirmed: Lyme disease Babesia Mycoplasma His initial treatment path included: 6 months of oral doxycycline 18 months of IV azithromycin Antiparasitics Mepron (for Babesia) Antifungals, antivirals, supplements, and Chinese herbs Despite years of treatment, nothing produced lasting improvement. Jesse describes his life during this period as being reduced to pill schedules, doctor visits, and survival mode. The Game Changer: Chelation and Ozone Therapy After nearly three years with minimal progress, Jesse's provider, Dr. Gerald (“Jerry”) T. Simons at the Morrison Center, suggested a more experimental approach: chelation combined with ozone therapy. Jesse underwent IV chelation and ozone therapy multiple times per week for several months. The results were dramatic. Nearly all of Jesse's symptoms resolved, and for the first time, he felt like himself again. Even years later, booster ozone treatments helped stop symptom flares before they escalated.

Meredith is the first therapist I ever hired at Best Life and she's awesome. Today's episode covers everything about ketamine assisted therapy, including step by step what the sessions are like, how you can now do it from the comfort of your home, the experiences she and I had with ketamine ourselves, ketamine assisted couples therapy, and the intersection of medication and therapy overall!If you're in CA, FL, MD, NJ or VA and you're interested in working with Meredith, check out her info below and email us at info@bestlifebehavioralhealth.com:https://www.bestlifebehavioralhealth.com/meredith-futernickTo get over 200 more episodes, most recent "Sex For Pleasure Within Marriage Over Time Is An Extremely New Idea," subscribe here! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://creators.spotify.com/pod/show/drpsychmomshow/subscribe⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ For my secret Facebook group, the "best money I've ever spent" according to numerous members: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.facebook.com/groups/drpsychmom⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠For coaching from DPM, visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.drpsychmom.com/coaching/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠For therapy or coaching, contact us at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.bestlifebehavioralhealth.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Date: January 17, 2026 Reference:  Casey et al. RSI Investigators and the Pragmatic Critical Care Research Group. Ketamine or Etomidate for Tracheal Intubation of Critically Ill Adults. NEJM. 2025 Dec The podcast is not uploading correctly. Please use this LINK to listen to Episode #500 until I resolve the issue. Guest Skeptic: Dr. Scott Weingart […] The post SGEM#500: Don't You Want Me – Etomidate or Ketamine for Induction of Critically Ill Patients first appeared on The Skeptics Guide to Emergency Medicine.

What if the music is doing more therapy than we realize?In this episode of The Vital Point Podcast, Jonathan sits down with Eric Sienknecht from Polaris Insight Center to explore the art, and the science—of music curation for ketamine-assisted therapy, breathwork, and other non-ordinary states of consciousness. From long-form DJ sets to holotropic-inspired “sonic containers,” we unpack why seamless transitions, tension-and-release, and rhythm can dramatically shape the inner landscape.Jonathan shares his surprising experience with at-home ketamine lozenges and how Polaris playlists helped turn sessions into coherent, emotionally intelligent journeys—where the music felt timed to the body's own processing. Together, they examine the nuanced line between staying with discomfort (shadow work) and honoring consent, safety, and nervous system limits, plus why learning to ask for what you need may be one of the most healing skills in altered states.You'll also hear practical integration strategies—like re-listening to your session playlist during the post-ketamine neuroplasticity window—along with a grounded conversation about the benefits and limitations of the new at-home ketamine landscape.**Please Note** this is an educational conversation, not medical advice. Ketamine affects people differently, and dosing—especially with at-home lozenges—should be determined with your prescribing clinician and followed exactly per your clinic's protocol. If anything feels unsafe or destabilizing, pause and get supportIn this conversation:How to structure a ketamine music journey (phases, arc, pacing)Rhythm vs. ambient: why “gentle” isn't always therapeuticThe role of seamless mixing in depth and immersionShadow tolerance, agency, and asking for supportIntegration practices that actually stickAt-home ketamine: accessibility, risks, and smart supportIf you've ever wondered how to create a safer, deeper, more meaningful inner journey—this episode is a map.Connect with Polaris Insight Center for KAP and clinician training at https://www.polarisinsight.com/ or https://www.instagram.com/polarisinsight/Join the Pathways to Integration newsletter at www.bluemagicalchemy.com

Green Day and Corey Feldman: We look back at New Year's Eve 2023 where Corey Feldman performed bad Billy Idol with Billie Joe Armstrong.Judy Haim's Statement: Judy Haim is completely fed up with the Goblin Ghoul and his recent allegations regarding Haim in the new Corey Feldman doc.Jezebel Sweet's Commentary: Jezebel drops some more commentary on the Corey Feldman Vs. The World documentary, we also check in on Corey's Twitter.COREY FELDMAN!, SHOW STOPPER!, LET'S JUST TALK!, DON CHEADLE!, BOOGIE NIGHTS!, JIM AND THEM IS POP CULTURE!, ANTI-COREY POD!, REAL ONES!, FILTH PIGS!, YEE-HAW!, WHAT IT DO MUSICAL!, STARTING LATE!, PATREON!, QUIET QUITTING!, FRICK VAPE!, PO BOX!, CRUISING!, AL PACINO!, LVL UP EXPO!, BIRTHDAY CAMEO!, JUSTIN HAWKINS!, NOT A BIRTHDAY GIFT!, ROAD TO 50K!, LVL UP EXPO!, KILL SWITCH!, ON A POLE!, NIT PICK!, YEAR!, FAIREST PODCAST!, LO SERV ILL!, BILLY IDOL HAIRCUT!, SUZIQ!, JUDY HAIM!, STATEMENT!, HOW DARE YOU!?, HEAVENLY BIRTHDAY!, LOST IT!, ABUSE!, DEAD PEOPLE!, THE TWO COREYS!, HATED!, DOMINIC BRASCIA!, MADE UP!, LIES!, JEZEBEL SWEET!, COREY'S ANGELS!, MATTHEW PERRY!, KETAMINE!, DRUGS!, HOT TUB!, BOILED!, SEASONING!, BUGS BUNNY!, COREY'S TWITTER!, K-HOLE!, STAND BY ME!, TOUR!, TROLLING!, COACH!, CHUMP! You can find the videos from this episode at our Discord RIGHT HERE!

Mood, motivation, and emotional resilience are not personality traits. They are biological systems. In this episode, you'll get the 12 greatest mood boosters on Earth, not as a clickbait supplement list, but as the real biological levers that control dopamine sensitivity, hormones, neuroplasticity, and energy production.Watch this episode on YouTube for the full video experience: https://www.youtube.com/@DaveAspreyBPR Host Dave Asprey sits down in Dubai with friend of the show, Lucas Aoun, founder of Ergogenic Health and INB4, for a deep, experience driven conversation on dopamine, mood, and performance. Lucas is Australia's leading biohacker, now based in Dubai, with a background in exercise science, naturopathy, and pharmacology. He is globally recognized for his work in dopamine regulation, testosterone optimization, and neurohormonal performance, and for rigorously testing protocols before recommending them. Together, Dave and Lucas explore how dopamine receptor upregulation changes motivation, mood, and resilience more effectively than stimulants alone. They break down compounds and systems discussed in the episode including solbutiamine, lithium orotate, sarcosine, inositol, uridine, testosterone, growth hormone, ketamine pathways, thyroid optimization, liver health, sleep quality, and desire regulation. The conversation also examines GLP-1 drugs, why they can blunt motivation, and how to think more strategically about long term mood and energy. This episode connects neuroscience, functional medicine, hormone biology, nootropics, and advanced biohacking ethics into a single framework for improving how you feel and function every day. Dave and Lucas also explain why experimentation requires guardrails, how to avoid tolerance and emotional flattening, and why upgrading baseline biology beats chasing quick fixes. You'll Learn: • Why dopamine sensitivity matters more than dopamine levels • How mood, motivation, and desire are regulated biologically • Which compounds and systems came up as major mood levers • How testosterone and growth hormone influence emotional resilience • Why some longevity drugs may reduce motivation and drive • How sleep depth and mitochondrial function affect mood • The role of neuroplasticity in emotional regulation • Why strategic testing beats random supplementation • How to improve mood without addiction or burnout • Where to start if you want sustainable energy and motivation Dave Asprey is a four time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade is the top podcast for people who want to take control of their biology, extend their longevity, and optimize every system in the body and mind. Each episode features cutting edge insights in health, performance, neuroscience, supplements, nutrition, hacking, emotional intelligence, and conscious living. Thank you to our sponsors! -LYMA | Go to https://lyma.sjv.io/gOQ545 and use code DAVE10 for 10% off the LYMA Laser. -Vibrant Blue Oils | Grab a full-size bottle for over 50% off at https://vibrantblueoils.com/dave. -AirDoctor | Go to https://airdoctorpro.com/daveasprey and save up to $300 on Air Purifiers Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights in health, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence, and conscious living. New episodes are released every Tuesday, Thursday, Friday, and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: dopamine sensitivity, dopamine receptors, mood boosters, motivation biology, dopamine supplements, natural mood boosters, biohacking dopamine, emotional resilience, anhedonia dopamine, focus and motivation, testosterone mood, growth hormone mood, ketamine alternatives, neuroplasticity mood, sleep and mood regulation, mitochondrial energy mood, GLP-1 dopamine effects, desire regulation, hormone optimization mood, dave asprey dopamine, lucas aoun biohacking, smarter not harder mood Resources: • Lucas's YouTube: https://www.youtube.com/c/boostyourbiology/ • Get My 2026 Biohacking Trends Report: https://daveasprey.com/2026-biohacking-trends-report/ • Join My Low-Oxalate 30-Day Challenge: https://daveasprey.com/2026-low-ox-reset/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Upgrade Collective: https://www.ourupgradecollective.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen: https://40yearsofzen.com Timestamps: 0:00 – Introduction & Dopamine Discussion 2:55 – Dopamine Compounds 6:29 – Lithium & Emotional Regulation 9:37 – Pain, Suffering & Biohacking Ethics 13:56 – Trumpet Vine & Amphetamine Alternatives 17:55 – Nootropics & Experimentation 20:27 – Sarcosine & Fast-Acting Antidepressants 23:53 – Sugar Tolerance & Inositol 27:01 – Testosterone & Hormone Optimization 33:48 – Natural Testosterone Optimization 37:36 – Anabolic Agents & SARMs 39:38 – Growth Hormone & MK-677 40:38 – Cabergoline & Prolactin 49:03 – Thyroid & Reverse T3 51:18 – Liver Health & Tudca 54:53 – Ketamine & Psychedelics 1:02:01 – Experimental Compounds 1:07:05 – Advanced Peptides & Compounds 1:13:19 – GLP-1 Agonists & Dopamine 1:14:44 – Closing Thoughts See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Hudson Elmore explains how Ketamine is being used in psychotherapy. He unpacks how patients are prepared for its use, what it's really like inside a ketamine therapy session, and the profound ways in which it can unlock trauma,treat depression, anxiety, and other mental health issues. Beyond the inapropriate uses of Ketamine, we take a close look at its utility in the treatment process and the trepidation that folks may have. Dr. Elmore is a Clinical Adult Psychiatrist, who serves as the medical director at Being Health, an integrated mental health practice in New York City. He has expertise in ketamine therapy and oversees interventional services at Being Health, where they offer IV and IM ketamine therapy as well as Spravato (intranasal esketamine). Dr. Elmore completed his training in Adult Psychiatry at New York University School of Medicine and Bellevue Hospital Center in New York City. He holds a Medical Degree from Georgetown University School of Medicine. www.beinghealth.co

Dr. Keith Humphreys is a professor of psychiatry and behavioral sciences at Stanford School of Medicine and a leading expert on treating addictions, drug laws and policy. We discuss all the major addictive substances and behaviors, including alcohol, opioids, gambling, stimulants, nicotine, cannabis and more, focusing on how genetics and certain use patterns shape addiction susceptibility. We discuss the best evidence-based tools for recovery, from 12-step programs to emerging treatments such as psychedelics and ibogaine. Anyone interested in making better choices for their health and/or seeking to avoid or overcome addictions ought to benefit from this episode. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman David: https://davidprotein.com/huberman BetterHelp: https://betterhelp.com/huberman Helix Sleep: https://helixsleep.com/huberman LMNT: https://drinklmnt.com/huberman Timestamps (00:00:58) Keith Humphreys (00:03:22) Addiction; Genetic Risk (00:09:14) Alcohol Use Disorder & Alcoholism; Genetic Predisposition & Addiction Risk (00:18:03) Sponsors: David & BetterHelp (00:20:37) Women & Alcohol Use; Young Adults; Cannabis Use (00:23:36) Health Benefit to Alcohol?, Red Wine, Cancer Risk; Social Pressure (00:31:47) Alcohol in Social Gatherings, Social Anxiety, Vulnerability, Work & Dates (00:37:41) Old vs New Cannabis & THC Levels; Smoked vs Edible Forms (00:44:38) Cannabis & Psychosis Risk; Cardiac Health; Youth Cannabis Use & Transition to Adulthood (00:52:29) Sponsor: AG1 (00:54:13) Industries of Addiction, Regulation; Gambling, Slot Machines, Novelty; Casinos (01:05:28) Decriminalization vs Legalization; Cannabis, Gateway Drug? (01:08:50) Psylocibin or LSD, Addiction Treatment; Microdosing, Clinical Trial Challenges (01:18:58) Sponsor: Helix Sleep (01:20:32) Brain Plasticity & Age; Ketamine, Depression, Transcranial Magnetic Stimulation (TMS) (01:28:10) SSRIs, Mass Shootings, Suicide, Side Effects; Drug Approval; Ibogaine & PTSD (01:36:10) Caffeine Addiction?; Stimulants & Rehab; Prescription Stimulants & ADHD (01:44:04) Nicotine, Mistaking Withdrawal for Benefit (01:47:24) Sponsor: LMNT (01:48:44) Tool: How to Talk to Someone with Addiction (01:55:23) Perception of Addicts, Character Defect, Pain (02:00:58) Overcoming Addiction, Immediate Rewards, AA; Addict & Co-Dependency? (02:09:53) Longterm Drug Use, Dopamine, Cues & Relapse; Social Media (02:16:21) Brain Stimulation, TMS; Homelessness, Substance Use & Rehab (02:26:11) Addiction Treatment Policy, Rehab & Insurance (02:29:08) Tool: 12-Step Programs, AA, Accessibility & Benefits (02:38:08) AA, Higher Power, Cult?; Flexibility, Tool: Open AA Meetings (02:44:38) GLP-1s, Weight Loss, Alcohol Addiction; Pharmaceutical Advertisements (02:52:39) Social Media Addiction, Tool: Avoiding Social Media Strategies (02:58:36) “Failure to Launch”, Youth, Video Games, Social Media; Recovery Pathways (03:04:13) AA as an Action Program, Tool: Try Different AA Meetings (03:08:21) Hospice, Death, Overcoming Fear of Death (03:13:54) Addiction to Escape Death?, Desire for Oblivion (03:18:11) Men vs Women & Addiction; Lying; Relapse; Fentanyl & Addiction Advice (03:24:27) Zero-Cost Support, YouTube, Spotify & Apple Follow, Reviews & Feedback, Sponsors, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

Eabhann O'Connor, a Consultant Urologist and an associate of the European Association Guidelines Committee.

Welcome to Cryptic Chronicles, where today we're venturing into the uncharted realms of the mind with an exploration of psychedelic trip reports. For centuries, psychedelics have been used as tools for spiritual awakening, healing, and unlocking the deepest corners of human consciousness. In this episode, we'll dive into firsthand accounts of profound, bizarre, and transformative psychedelic experiences—journeys that blur the lines between reality, illusion, and higher dimensions. From encounters with otherworldly beings to the unraveling of time and ego, these stories offer a glimpse into the psychedelic frontier that mystics, psychonauts, and seekers have long explored. Buckle up as we traverse these mind-bending landscapes and question what lies beyond the veil of ordinary perception. SOURCES: https://www.erowid.org/experiences/exp.php?ID=116163 https://www.erowid.org/experiences/exp.php?ID=43906 https://www.erowid.org/experiences/exp.php?ID=1839 https://www.erowid.org/experiences/exp.php?ID=31979 https://www.erowid.org/experiences/exp.php?ID=45012 https://www.erowid.org/experiences/exp.php?ID=96004 https://www.erowid.org/experiences/exp.php?ID=30320 BUY MERCH! https://httpscrypticchroniclescom.creator-spring.com/ Patreon: https://www.patreon.com/c/crypticchronicles Magic Mind: https://magicmind.com/CRYPTICCR20 Use code: CRYPTICCR20

This Week on Dopey! Dave kicks off the Friday episode by celebrating Dopey OG Leah Lumberg's 17 years of sobriety, sharing heartfelt Spotify listener comments (with spirited debates over Breaking Bad characters and more love for the recent Cosmo Lumbino interview), and playing a raw voicemail from Lane opening up about self-medicating with crushed stimulants, kratom, and weed amid depression and a breakup—reminding everyone Dopey welcomes voices from all sides of the struggle. The heart of the show is a deep, hilarious, and profoundly honest conversation with returning guest Hank Azaria, who gets real about his teenage battles with anorexia and bulimia, maintaining his impressive physique through disciplined fitness and calorie tracking, finding primary recovery in Adult Children of Alcoholics (ACA) work (including a full breakdown of the ACA "laundry list" traits), his enduring love for voicing Moe on The Simpsons, the looming AI threat to voice actors, his Bruce Springsteen tribute band (complete with Bruce's personal thumbs-up), and a thoughtful take on cultural extremism as the real enemy. Packed with lightning-round fun, Mets passion, and classic Dopey vulnerability. All that and more on this brand new episode of that good old dopey show!  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. H sits down with Dr. Elizabeth Fenstermacher, Medical Director of the TMS Clinic at the University of Colorado- Anschutz to explore the growing role of TMS and neuromodulation in psychiatry.  They explore questions such as:•How should we think about TMS vs ketamine in the treatment of depression? Trauma? OCD?•Who are the best candidates for TMS? •What are the relative merits of intensive TMS (SAINT) vs standard protocols?•How might TMS and ketamine work together to promote psychiatric stability?Support the show! https://www.buzzsprout.com/396871/supportDr. Elizabeth Fenstermacherhttps://som.cuanschutz.edu/Profiles/Faculty/Profile/33013Patient selection for TMS- Case report with Dr. Fenstermacherhttps://journals.lww.com/hrpjournal/fulltext/2025/11000/case_report__personalizing_transcranial_magnetic.3.aspxExplore the full BFTA Content Catalog:A listener-built, human-curated index of every Back From The Abyss episode to help you find themes, topics, and episode formats of interest.Best viewed on a laptop or desktop (not mobile).Content Catalog (in Google Sheets): https://bftapod.short.gy/index"I Love You, I Hate You, Are You My Mom?"  An intensive experiential workshop exploring transference with Dr. H and Dr. Hillary McBride, Feb 4th-6th 2026 in Joshua Tree, CA https://www.craigheacockmd.com/i-love-you-i-hate-you-are-you-my-mom/BFTA episode recommendations/Podcast pagehttps://www.craigheacockmd.com/podcast-page/Support the show

In this episode, Will Van Derveer, MD joins to unpack what we know about which psychedelic medicines are best suited to particular mental health conditions. Dr. Van Derveer has trained several thousand mental health professionals in psychedelic-assisted psychotherapy, provided ketamine assisted therapy to hundreds of people, and has staffed MDMA therapy trials with MAPS. His book, Psychedelic Therapy: A Revolutionary Approach to Restoring Your Mental Health and Reclaiming Your Life, will be published by Shambala in the spring of 2026. In this conversation, Dr. Van Derveer offers a clinician's framework for thinking through how different psychedelic medicines may align with different mental health conditions. He explores how factors such as anxiety levels, trauma history, prior psychedelic experience, and a person's orientation toward spiritual versus medical healing shape treatment decisions. Across discussions of anxiety, depression, PTSD, OCD, and eating disorders, Dr. Van Derveer reflects on the relative roles of ketamine, psilocybin, MDMA, and emerging short-acting psychedelics, while underscoring the importance of community, and integration. Throughout, he returns to a central theme: many conditions labeled as psychiatric may also reflect deeper forms of disconnection—social, existential, and spiritual—and psychedelic therapies can be powerful tools for restoring those lost connections when used thoughtfully.   In this episode, you'll hear: Why safety, medication interactions, and psychiatric history must come before all other considerations The difference between clinical and ceremonial approaches to psychedelic healing Considering when group versus individual approaches to psychedelic therapy may be best suited for a particular patient How ketamine, psilocybin, and MDMA may play distinct roles in treating anxiety and depression Considerations of dose, tolerance, and maintenance sessions for ketamine treatments Why MDMA-assisted therapy stands out for chronic and severe PTSD Dr. Van Derveer's perspective on emerging psychedelic medicines and the future of treatment   Quotes: "As time wears on, I lean more toward the group dynamic [for psychedelic therapy] because of the power of community and healing in community. And also, of course, it can help mitigate the cost of access for people." [8:24] "There's a lot of conversation about ibogaine right now, and I think it's an incredibly powerful, beautiful, sacred, ancient medicine that has a role. But it has a lot more porcupine quills on it than, say, ketamine or MDMA." [27:16] "In acute suicidality, I think ketamine is the treatment of choice. There's nothing like it. … it can be quite impressive how quickly suicidal thoughts melt away. But it is a short game because often it doesn't stick for people. And that's a huge drawback." [28:39] "We know that there are clear associations between chronic depression and high levels of inflammation in the body and also in the brain. Ketamine and psilocybin both have strong anti-inflammatory effects. But it seems like somehow the pathways that psilocybin is working on… tends to produce longer term benefits." [30:10] "I tend to think that spiritual connection—in whatever your language is, whatever your metaphors are, however you think about it—is something that we need to think about for health overall." [40:21]   Links: Dr. Van Derveer on LinkedIn Dr. Van Derveer on Instagram Dr. Van Derveer on X Dr. Van Derveer's forthcoming book, Psychedelic Therapy: A Revolutionary Approach to Restoring Your Mental Health and Reclaiming Your Life Integrative Psychiatry Institution website  Previous episode: Is Psilocybin Safe for Me? with Seth Mehr, MD Psychedelic Medicine Association Porangui

🧭 REBEL Rundown 📌 Key Points 💀 Mortality: No statistically significant difference in 28-day mortality between ketamine vs etomidate for intubation in critically ill patients, though there was a ~1% absolute difference favoring ketamine. 📉🫀⚠️ Hemodynamics: Ketamine induction was associated with more cardiovascular collapse, mainly driven by new/increased vasopressor use (dose escalation or addition of a vasoactive agent). 💉⬆️ Click here for Direct Download of the Podcast. 📝 Introduction Etomidate or ketamine? The debate over the ideal agent for emergency rapid sequence intubation (RSI) has raged for years with no clear winner. Etomidate has been touted in the past for its rapid onset and minimal intrinsic effects on hemodynamics. However, the drug is well known as a transient adrenal suppressant though the impact of this suppression isn’t clear. Ketamine has risen in recent years as an alternative, due to its perceived hemodynamic stability, analgesic properties and absence of adrenal suppression. Additionally, recent data points towards improved mortality when ketamine was selected over etomidate (Kotani 2023). High quality randomized controlled trials are needed to further elucidate which agent should be selected in critically ill patients. 🧾 Paper Casey JD et al. Ketamine or etomidate for tracheal intubation of critically ill adults. NEJM 2025. PMID: 41369227 🔙Previously Covered On REBEL REBEL EM: The EvK Trial: Ketamine vs Etomidate for Rapid Sequence IntubationREBEL EM: From Debate to Data: Emerging Insights into RSI Induction with Ketamine vs Etomidate ️ What They Did CLINICAL QUESTION In critically ill adults undergoing tracheal intubation, does the use of ketamine instead of etomidate result in improved 28 day mortality? STUDY DESIGN Multicenter, randomized, open-label trial in both emergency departments and ICUs. POPULATION Inclusion Criteria:Critically ill patients > 18 years of age undergoing tracheal intubation with the use of an induction agentExclusion Criteria:Known pregnancyPrisonersPrimary diagnosis of traumaNeed for immediate intubation precluding randomizationClinicians determined that the use of ketamine or etomidate was either necessary or contraindicated INTERVENTION & COMPARATOR Intervention (HFNC Group):Ketamine administered based on a provided nomogram: full dose (2.0 mg/kg), intermediate dose (1.5 mg/kg) or reduced dose (1.0 mg/kg)Comparator (BPAP Group):Etomidate administered based on a provided nomogram: full dose (0.3 mg/kg), intermediate dose (0.25 mg/kg) or reduced dose (0.2 mg/kg) OUTCOMES Primary: In-hospital death from any cause by day 28.Secondary:Cardiovascular collapse during intubation defined as SBP < 65 mm Hg, receipt of new or increased dose of vasopressors or cardiac arrest.Exploratory Procedural:Lowest systolic blood pressureLowest systolic blood pressure below 80 mmHgHighest systolic blood pressure above 180 mmHgLowest oxygen saturationLowest oxygen saturation below 80%Successful first attempt intubationTime from induction to intubationExploratory Clinical:Number of ventilator free daysVasopressor-free daysICU free days Safety: Systolic blood pressure at 24 hours after enrollmentOngoing receipt of vasopressors at 24 hours 📈 Results: 2365 patients were randomizedKetamine: 1176Etomidate: 1189> 99% of patients received the drug they were randomized to receiveNMBA: 69% of patients in both groups received rocuronium~ 95% of patients had video laryngoscopy for the primary intubation attempt 💥 Critical Results 💪 Strengths Multicenter ED + ICU cohort of critically ill patients → improves external validityStrong randomization → balanced baseline characteristicsRight population for the question → appropriately focused on a sick cohort where induction choice matters mostHigh protocol adherence → most patients received the agent they were randomized toExcellent follow-up → minimal loss to follow-up / outcome capture ⚠️ Limitations No blinding → potential performance/resuscitation biasTrauma excluded → limits applicability to peri-intubation trauma careCase-mix skewed toward septic shock → may reduce generalizability to other shock etiologiesPower assumptions → designed to detect a 5% mortality difference (possibly overly ambitious)Equipoise-only enrollment → excluded patients with clear indication/contraindication → selection bias + reduced real-world applicabilityComposite secondary outcome with non-equivalent endpoints (e.g., cardiac arrest vs vasopressor titration)Ketamine dosing by actual body weight (vs ideal) → may have increased dose/exposure in some patients 🗣️ Discussion The increase in cardiovascular collapse seen with ketamine was driven by the “new or increased vasopressor use” piece of the composite outcome not by the more clinically relevant severe hypotension (SBP < 65 mm Hg) or cardiac arrest.The increase in CV collapse is a secondary outcome and hypothesis generating onlyCare beyond induction agent isn’t clearly delineated and may have varied between groupsReasons why there was more CV collapse in the ketamine group:Patients in the etomidate group were more likely to be on pressors or have pressor increases prior to induction agent administrationKetamine has analgesic properties which may affect hemodynamics (etomidate does not have analgesic effects)The standard ketamine dose of 2 mg/kg is higher than the induction dose used by most (1-1.5 mg/kg)Ketamine dosing was based on actual body weight though ideal body weight dosing is more accepted. This may have resulted in unnecessarily large ketamine doses that may have had a greater effect on hemodynamics.This is a study of patients with clinical equipoisePatients who the clinician determined would clearly benefit from one agent or the other or in whom one agent or the other was contraindicated were excluded from the study.This may add a selection bias to the results.Clinicians were not blinded to the induction agent administeredThe absence of blinding can introduce bias.For instance, knowledge of the agent the patient was randomized to may result in different resuscitative treatment prior to intubation.An induction agent nomorgram was provided to allow clinicians to choose their induction dose depending on patient stability.A 5% difference in mortality may be overly ambitious. As Josh Farkas points out in his post on this article, PCI for STEMI only has a 3% absolute difference in mortality versus standard care.The 1% absolute difference in mortality while not statistically significant would be clinically significant if it was real. The study would have to be much larger to show a statistically significant 1% difference.About 2% of patients in each group received additional medications during induction (propofol, benzodiazepines, opiates). It is unclear why these agents were selected in specific cases and how they may have affected the outcomes in question. 📘 Author's Conclusion “Among critically ill adults undergoing tracheal intubation, the use of ketamine to induce anesthesia did not result in a significantly lower incidence of in-hospital death by day 28 than etomidate.“ 💬 Our Conclusion In this well done RCT, induction with ketamine did not result in a lower 28-day mortality when compared to induction with etomidate in critically ill adults. The secondary outcome of an increase in cardiovascular collapse is interesting and should be studied more in the future. 🚨 Clinical Bottom Line This data should not drive clinicians to abandon the use of ketamine in RSI. To the contrary, the study leaves open the possibility of a clinically meaningful difference in mortality favoring ketamine that may be borne out in a larger study. However, etomidate can be considered as a first-line option for RSI and may be the superior drug in patients at high-risk for cardiovascular decompensation. Post Peer Reviewed By: Post Peer Reviewed By: Mark Ramzy, DO (X: @MRamzyDO), Frank Lodeserto, MD and Anand Swaminathan, MD (X: @EMSwami) 📚 References Kotani Y et al. Etomidate as an induction agent for endotracheal intubation in critically ill patients: a meta-analysis of randomized trials J Crit Care 2023;77:154317. PMID: 37127020 👤Associate Author Anand Swaminathan MD, MPH All Things REBEL EM Meet The Team 🔎 Your Deep-Dive Starts Here The RSI Trial: Ketamine vs Etomidate in Rapid Sequence Intubation Etomidate or ketamine? The debate over the ideal agent for emergency rapid sequence ... Resuscitation Read More REBEL Cast Ep120: Etomidate vs Ketamine for RSI in the ED? Background: Standard rapid sequence intubation (RSI) in the emergency department involves administration of ... Procedures and Skills Read More The post The RSI Trial: Ketamine vs Etomidate in Rapid Sequence Intubation appeared first on REBEL EM - Emergency Medicine Blog.

See omnystudio.com/listener for privacy information.

This episode shows you how light, vibration, and frequency-based technology can shift your brain state in minutes, unlock deep neuroplasticity, release stored trauma, and create coherence that normally takes years of meditation or psychedelic training. You will learn how these tools support performance, resilience, mitochondria, emotional regulation, and advanced biohacking. Watch this episode on YouTube for the full video experience: https://www.youtube.com/@DaveAspreyBPR Host Dave Asprey sits down with master healer Raffaele Gianfrancesco, whose work draws on energy medicine, Egyptian color healing, vibroacoustics, and light based entrainment. Raffaele trained in the Barbara Brennan lineage and spent years developing methods that shut down the default mode network, activate the thalamocortical circuit, and move people into deep meditative and altered states within minutes. His technology has attracted the attention of consciousness researchers, advanced meditation schools, ketamine clinics, and U. S. Air Force programs studying human resilience and pilot performance. Dave and Raffaele break down how vibroacoustic sound, harmonics, cymatics, and flickering light therapy guide the brain into gamma, delta, epsilon, and high resonance states that support clarity, emotional release, and rapid state change. Raffaele explains how vibration affects fascia and trauma storage, how light influences the cerebrospinal fluid and pineal gland, and why coherence is the key to shifting consciousness. They discuss ketamine assisted therapy, remote viewing, the Monroe Institute, the relationship between frequencies and brain states, the history of flickering light therapy, and how certain frequencies help loosen trauma patterns stored in the body. You'll Learn: • How vibroacoustic sound and coherent light shut down the default mode network • Why fascia, trauma memory, and cerebrospinal fluid respond to vibration • How flicker based entrainment maps to gamma, delta, and theta brain states • Why the Air Force studies these tools for resilience and reaction speed • How ketamine combines with vibration and light to improve neuroplasticity • Why coherence, awe, and safety cues are essential for deep emotional release • What cymatics, harmonics, and frequency patterns reveal about consciousness Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights in health, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence, and conscious living. New episodes are released every Tuesday, Thursday, Friday, and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: vibroacoustic therapy, flickering light therapy, consciousness technology, brainwave entrainment, cymatics healing, trauma release tools, ketamine neuroplasticity, default mode network reset, cerebrospinal fluid flow, energy medicine, Barbara Brennan healing, harmonic frequencies, gamma brain states, theta induction, somatic healing, astral plane experiences, remote viewing training, Monroe Institute methods, coherence training, vibration based meditation **https://roxiva.com/dave - for $1,000 off when you purchase the light and vibroacoustic bed together. ** Resources: • RoXiva Website: https://roxiva.com/dave • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Upgrade Collective: https://www.ourupgradecollective.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen: https://40yearsofzen.com Timestamps: • 0:00 - Introduction • 1:14 - Vibroacoustic Technology • 4:08 - Energy Medicine and Healing • 10:06 - Coherence and Harmonics • 13:47 - Flickering Light Therapy • 16:10 - Stanislav Grof and LSD • 18:49 - Soul Sickness and Consciousness • 21:53 - Ayahuasca and Astral Plane • 28:36 - Psychedelics and Ego Death • 31:23 - Ketamine and Neuroplasticity • 37:31 - Trauma and Presence • 41:08 - Harmonics and Brain Frequencies • 44:04 - Flicker Fusion and Safety • 46:43 - Remote Viewing and Monroe Institute • 48:23 - Cerebrospinal Fluid and Consciousness • 50:32 - Product Details and Pricing See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.